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„If it were not for the great variability among individuals 
 medicine might as well be a science and not an art.“  
Sir William Osler, 1892 
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1. INTRODUCTION  
 
One of the many reasons that pharmacology remains as much art as science is the 
extraordinary variation in patient response to medications (Lanfear 2007). Variation of genetic 
variability at the pharmacogenetically relevant genes is the most important cause of variable 
drug response.  
Ethnic differences in drug response are well known, thus the optimal drug dose vary 
between populations of different origin. The population of Hungary is comprised largely of 
Hungarians, however, many ethnic minorities also reside here, with the Roma forming the 
largest group. It is well known, Roma minorities live all around the world, but the genetic 
profile of this minority is less studied. The Roma differ from all the populations of countries 
they live because of their origin. Evidences have been presented that Roma people are of Indian 
origin (Morar 2004b, Gresham 2001b, McKee 1997, Hajioff 2000, Kalaydjieva 2001b, 
Kalaydjieva 2001a, Mastana 1992), and thus have different genetic structure than people of 
Caucasian origin. On the historical basis Hungarians are from the eastern side of the Ural 
Mountains (Nadasi 2007, Semino 2000b), thus the ancestry of the ancient Magyars is also 
differs from the Europeans. Thus the different origin of Roma and Hungarians from 
neighbouring populations in Europe is important in the clinical therapy they receive. 
In conclusion, understanding of human genomic variation and its application in 
pharmacogenetics might shift our focus away from interindividual differences towards 
interpopulation differences (Daar 2005). 
 
1.1. Individual variation of drug response and adverse drug reactions 
 
Individual variation in drug response and adverse effects is a substantial problem. Many 
factors can affect patient’s response to the drug. Optimal drugs and drug doses depend on age, 
gender, body weight, co-morbidity, organ functions, disease states, drug-drug interactions, 
lifestyle, culture, race/ethnicity, genetics, smoking, diet (Brockmoller 2008). However, genetic 
variation can account for as much as 95% of variability in drug disposition and effect (Kalow 
1998). As the main cause of the variation in drug response, attention has focused on the genetic 
polymorphisms. Single nucleotide polymorphism (SNP) of DNA produces a variation in drug 
responses and has become a representative research target in pharmacogenetics. Polymorphisms 
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of genes encoding drug metabolism enzymes, drug transporters, and drug receptors have been 
reported and association with drugeffect has been clarified. 
More than 50% of ADRs are dose-related (Brockmoller 2008). Of the evaluable drug 
products 21% had dose changes (Cross 2002). ADR’s were experienced by 10% of hospitalized 
patients and were estimated to be the 4th or the 6th leading cause of death in the USA (Lazarou 
1998). Fifty nine percent of drugs causing ADRs are metabolized by polymorphic enzymes 
while only 7-22% of other randomly selected drugs are substrates for polymorphic enzymes 
(Phillips 2001). One priority area of pharmacogenetic research is to predict serious ADRs (Need 
2005). 
The clinical consequences of ADRs were observed all around the world. In the UK ~7 % 
of patients are affected by adverse drug reactions. These ADRs cost about £380 million a year 
(Wiffen 2002). In the US an estimated 2.216.000 patients suffered from serious ADRs, leading 
to approximately 106.000 patient death, and making ADR the fourth to sixth leading cause of 
death in 1994 (Lazarou 1998). 
 
1.2. Genetic variation of the human population, interethnic differences in drug response 
 
Genetic differences between people contribute to interindividual differences in the 
response to many drugs. Findings of the Human Genome Project cleared that 99.9 % of the 
information in the estimated 20.000 human genes is identical from one person to the next. The 
small differences in the remaining 0.1 % of genes are the key to each individual 
(www.genetics.edu.au). Very often the variability in DNA consists of only one nucleotide base 
change, and if this occurs in more than 100 subjects at a given position in the DNA, it is referred 
to as a single nucleotide polymorphism. SNPs make up about 90% of all human genetic 
variation. In 2008, about 12 million SNPs and a large amount of other types of genetic variation 
were known in the human genome (Brockmoller 2008). The remainder of the variation is caused 
by insertions, deletions, tandem repeats and microsatellites (Marsh 2006). 
It is known, that many polymorphisms that influence drug response and which probably 
contribute significantly to phenotypic variation in drug response have significant allele 
frequency differences among racial or ethnic groups (Tate 2004, Engen 2006, Evans 1999a). In 
1920s inter-ethnic variations in response to medication were observed. Paskind investigated the 
different effect of atropine sulphate on Caucasian and African-American people in USA as first 
  7  
(Paskind 1921). Recent studies report differences between African and non-African population 
groups in the structure of sequence variation in the human genome (Tishkoff 2003). Known 
interethnic difference exist in warfarin dosing, with the lowest among Asian-Americans (24 
mg), followed by Hispanics (31 mg), Caucasians (36 mg) and highest among African-
Americans (43 mg) (Dang 2005). This fits with recent data showing that VKORC1 haplotypes 
predicting low dose are more common in Asian-American populations (89%) and less common 
in African-Americans (14%) than in European Americans (37%) (Rieder 2005).  
Geographic patterns of genetic variation, including variation at drug metabolizing 
enzyme loci and drug targets, indicate that geographic structuring of inter-individual variation in 
drug response may occur frequently. This geographic distribution of certain variants has 
highlighted the possible importance of average differences in drug response across populations 
(Wilson 2001). For this reason we need to take into account not just differences between the 
genotypes of individuals, but the differences in genotypes between population groups of 
different origin and the substantial variation between the five main racial groups, which are 
based on continental ancestry (Daar 2005). 
In conclusion, understanding of human genomic variation and its application in 
pharmacogenetics might shift our focus away from interindividual differences towards 
interpopulation differences (Daar 2005). Thus race or ethnicity will usually be a far inferior 
guide to response than direct determination of the underlying genetic variant (Need 2005). 
 
 
1.3. Pharmacogenetics, pharmacogenomics  
 
Individual variation in response to drugs is a substantial clinical problem. Individuality 
in drug response can be inherited. The genetically determined variability in drug response 
defines the research area known as pharmacogenetics. Pharmacogenetics has evolved in the past 
50 years to a major driving force of clinical pharmacology. The first concept of 
pharmacogenetics was originated from Motulsky in 1957 (Motulsky 1957). The term 
pharmacogenetics was suggested by Vogel in 1959 (Vogel 1959), and the first book on the 
subject was written by Kalow (Kalow 1998). Evidence for an inherited basis for drug response 
phenotypes dates to the 1950s, when Alving et al. observed that hemolysis during anti-malarial 
drugs treatment was due to an enzymatic defect for the glucose-6-phosphate dehydrogenase 
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(ALVING 1956). The first molecular defect was identified by Frank Gonzalez in the late 1980s 
(Gonzalez 1988). The term pharmacogenetics is used to cover both germline and somatic 
predictors of drug response (Goldstein 2003). One of main directions in development of 
pharmacogenetics is identifying genes and allelic variants of genes that affect our response to 
drugs (Wolf 1999, Wolf 2000). To date, polymorphisms of genes encoding drug metabolism 
enzymes, drug transporters, and drug receptors, which are involved in drug responses, have been 
reported and in some of them the association between pharmacodynamics and drug efficacy has 
been clarified (Evans 1999a, Goldstein 2003). 
Pharmacogenomics is an apparently new science about how the systematic identification 
of all the human genes, their products, interindividual variation, intraindividual variation in 
expression and function can be used both to predict the right treatment in individual patients and 
to design new drugs. 
There are differences between pharmacogenetics and pharmacogenomics. Accordingly, 
most of scientists use pharmacogenetics to depict the study of single genes and their effects on 
interindividual differences in drug metabolizing enzymes, and pharmacogenomics usually used 
in broader context, to depict the study of not just single genes, but the functions and interactions 
of all genes in the genome in the overall variability of drug response, whether this is caused by 
pharmacokinetics, pharmacodynamics or both. Some have distinguished between 
pharmacogenetics and pharmacogenomics on the basis of either the type of genomic information 
or the quantity (Goldstein 2003). The differences between the pharmacogenetics and 
pharmacogenomics are the initial approach of the science. Pharmacogenetics is based on an 
unexpected drug response result and looks for a genetic cause, while pharmacogenomics looks 
for genetic differences within a population that explain certain observed responses to a drug or 
susceptibility to a health problem (www.genetics.edu.au). 
To summarize, classical pharmacogenetics has searched the genes for an abnormal drug 
response of proven clinical value, whereas pharmacogenomics presently and in the future will 
search the bearing if any of known genes, SNPs or haplotypes. 
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1.4. Individualized drug therapy 
 
Clinical significance of personalized medicine and understanding of genetic role of 
variable drug response is an important goal of biomedical research (Wilson 2001). Patients with 
the same diagnosis may respond in different ways to the same drug. In the best case the 
prescribed drug is not toxic and beneficial, but in some cases it can be also not beneficial. In 
other cases the treatment can be toxic, but beneficial. The worse occurrence is when the drug is 
toxic and also not beneficial (Figure 1.). 
 
 
Figure 1. Individulized therapy means the use of pharmacogenomics to select the right drug for 
the right person prior to medication prescription (Marsh 2006) 
 
Through the use of pharmacogenetics, physicians will be able to profile variations 
between indiviadual’s DNA to predict responses to a particular medicine. Pharmacogenetics will 
have impact on medical care and medical aid at multiple levels (Roses 2000). Moreover, 
pharmacogenetic testing may provide the first example of a mechanism whereby DNA based 
testing can be applied to populations (Wolf 1999). The intersection of pharmacogenomics and 
medicine has the potential to yield a new set of molecular diagnostic tools that can be used to 
individualize and optimize drug therapy (Evans 2004). 
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1.5. Cytochrome P450s and cytochrome P450 2C9 (CYP2C9) genetics 
 
Cytochrome P450 system plays a key role in the drug metabolism. The cytochrome 
P450s are a multigene family of enzymes found predominantly in the liver that are responsible 
for the metabolic elimination of most of the drugs currently used in medicine (Wolf 1999). Most 
drugs are lipophilic compounds that are mainly eliminated by oxidation catalyzed by the 
cytochrome P450 (CYP) enzyme system in the liver. The total number of CYP genes in all 
species is 270, but the human CYP superfamily consists of 57 CYP genes and 33 pseudogenes 
organized in 18 families and 42 subfamilies. The endogenous substrates for CYP include fatty 
acids, eicosanoids, sterols and steroids, bile acids, vitamin D, retinoids and uroporphyrogens. 
The CYP also represent the most important way for detoxification of many foreign chemical 
including drugs. The drug metabolizing CYP belong to families 1, 2 and 3. Phenotypes of P450 
are divided into different groups. Extensive metabolizer (EM) that shows regular metabolic 
capacity, poor metabolizer (PM) that shows low metabolic capacity, and intermediate 
metabolizer (IM) that shows the metabolic capacity between the PM and the EM. In addition, 
the categorization includes the ultra-rapid metabolizer (UM) that shows higher metabolic 
capacity than the EM (Hiratsuka 2006). 
Cytochrome P450 (CYP) 2C9 [MIM 601130] is one of the most important enzymes in 
human drug metabolism and its genetic polymorphisms are known to contribute to 
interindividual and interethnic variations in the metabolism of several drugs in humans (Daly 
1993, Bertilsson 1995, Rogers 2002). CYP2C9 is involved in the metabolism of 10-20% of all 
drugs, including many clinically important pharmaceuticals such as coumarin anticoagulants, 
losartan, tolbutamide, sulfonylurea drugs, angiotensin II blockers, nonsteroidal anti-
inflammatory drugs (NSAIDS) and phenytoin, some with narrow therapeutic index (Rogers 
2002, Daly 2003, Takahashi 2006, Goldstein 1994, Xie 2001, Kirchheiner 2005, Garcia-Martin 
2006, Miners 1998). A total number of drugs metabolized by CYP2C9 enzyme are more than 
60. 
To date 34 CYP2C9 variant alleles have been reported (http://www.cypalleles.ki.se/). 
CYP2C9*1 is the wild-type allele, and besides there are two important single nucleotide 
polymorphisms the CYP2C9*2 (C430T, exon 3) associated with a functionally important 
Arg144Cys substitution and the CYP2C9*3 (A1075C, exon 7) associated with another 
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important Ile359Leu substitution. Both variants are encoding enzymes with reduced enzymatic 
activity (Xie 2001, Ingelman-Sundberg 2005, Aithal 1999). Several studies show that *3 is 
associated with a lower intrinsic clearance of substrate drugs than *2; and CYP2C9*3 has less 
than 5% of the activity of the wild-type enzyme, whereas CYP2C9*2 has about 12% of that 
activity (Aithal 1999, Sullivan-Klose 1996, Rettie 1999). However, the extent of reduction in 
catalytic activity caused by each variant is substrate specific (Takanashi 2000). In Caucasians 
the frequencies of the 6 different genotypes are 65-70 %, 15-20 % and 8-10 % for 
CYP2C9*1/*1, CYP2C9*1/*2 and CYP2C9*1/*3, respectively. The poor metabolizer 
genotypes CYP2C9*2/*2, CYP2C9*3/*3 and CYP2C9*2/*3 each occur in about 1-2%. 
Tolbutamide has been proposed to be a candidate for a model drug to probe for CYP2C9. The 
CYP2C9 polymorphisms are important determinants of the warfarin dose. The presence of 
CYP2C9 polymorphisms is associated with a reduction in the metabolism of S-warfarin 
(Higashi 2002, Takahashi 1998). 
The allelic variants of human cytochrome P450 CYP2C9 gene vary in frequency among 
different ethnic groups (Xie 2001, Scordo 2004, Sipeky 2009b). 
 
1.6. Vitamin K epoxide reductase complex subunit 1 (VKORC1) genetics 
 
VKORC1 [MIM 608547] is the key enzyme of the vitamin K cycle and the molecular 
target of coumarins. Coumarins, including warfarin, acenocoumarol and phenprocoumon, are 
the fundamental drugs used for long-term treatment of thromboembolic diseases (Oldenburg 
2007a, D'Andrea 2008). They exhibit large interindividual and interethnic variability in the dose 
requirement (El Rouby 2004, Kamali 2006, Sconce 2006). The vitamin K epoxide reductase 
complex subunit 1 (VKORC1) is the warfarin-sensitive enzyme in vitamin K metabolism and 
biosynthesis of vitamin K-dependent blood coagulation factors. Warfarin influences blood 
coagulation by inhibiting the VKORC1, thereby preventing the vitamin K regeneration, which 
leads to a reduced amount of vitamin K available to serve as a cofactor for gamma carboxylation 
of clotting factrors (II, VII, IX and X) and the anticoagulant protein C and S (Li 2004, Rost 
2004, Stafford 2005). Genetic variations of VKORC1 gene can greatly affect the individual 
response to coumarins (Schalekamp 2007, Oldenburg 2007b, Gage 2008, Rieder 2005, Geisen 
2005). Mutations in VKORC1 result in different phenotypes: resistance to coumarin derivates 
(warfarin resistance, WR) or warfarin sensitivity, or in a rare bleeding disorder known as 
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multiple coagulation factor deficiency type 2 (VKCFD2) (Rost 2004, Oldenburg 2000). 
VKORC1 has greatly improved our understanding of the vitamin K cycle and has led to the 
translation of basic research into clinical practice (Oldenburg 2007b). 
The relatively recent discovery of the haplotype structure of the human genome, and the 
effect that this has on SNP inheritance, could help to simplify and reduce the costs of 
genotyping (Daar 2005). 
Besides some common missens mutations in VKORC1 gene, the haplotypes already 
have been identified, which are known to affect the warfarin response (Carlquist 2006, 
Aquilante 2006, D'Andrea 2005, Wadelius 2005, Yuan 2005, Sconce 2005). Most of the 
VKORC1 haplotype literature uses either the terminology of Reider et al (Rieder 2005) or 
Geisen et al (Geisen 2005) when describing VKORC1 haplotypes. We decided to use the 
haplotype nomenclature of Geisen et al. The major natural VKORC1 haplotypes are determined 
by the combinations of the G-1639A, G9041A, C6009T haplotype tagging SNP-s of VKORC1 
gene; with this approach the ancestral VKORC1*1, and three further major haplotypes, the 
VKORC1*2, *3, and *4 can be differentiated. The VKORC1*1 the putative ancestral haplotype, 
is characterized by the presence of ancestral allele of G1639A, G9041A, and C6009T 
polymorphisms. The VKORC1*2 haplotype is characterized by the presence of 1639A, G9041, 
and C6009 SNP combination. The VKORC1*3 haplotype is characterized by the 9041A, 
G1639, and C6009 SNPs. The VKORC1*4 haplotype is characterized by the presence of 6009T, 
G1639, and G9041 combination (Sipeky 2009a). Specific haplotype determining 
polymorphisms of the VKORC1 gene are summarized in Table 1. and the identification of 
haplotypes in Table 2.  
Table 1. Studied polymorphisms of the VKORC1 gene 
Nucleotide position
Marker 
DNA cDNA 
Nucleotide 
change Gene region rs 
M2 3673 c. -1639 G>A Promoter 9923231 
M23 9041 492+134 G>A 3'-region 7294 
M16 6009 173+525 C>T Intron1 17708472 
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Table 2. Haplotype determining polymorphisms of the VKORC1 gene 
Haplotype G-1639A G9041A C6009T
VKORC1*1 G G C 
VKORC1*2 A G C 
VKORC1*3 G A C 
VKORC1*4 G G T 
 
Interestingly, the VKORC1*1, the ancestral haplotype seems to only occur at high 
frequencies in populations of African origin, but VKORC1*1 is not the most common haplotype 
in the African population (Geisen 2005). 
Haplotype *2 (H1 and H2, haplotype group A (defined by Rieder et al.)) includes a SNP 
in the promoter region (c. -1639 G>A, rs9923231) and is associated with response to a lower 
dose of warfarin. This polymorphism was shown to disrupt an E-box transcription factor 
binding-site, resulting in a significantly reduced promoter activity. VKORC*2 haplotype has 
pronounced differences in its frequency by different ethnic groups. VKORC1*2 is the 
predominant haplotype in the Asian population (around 90%), and it is also quite common 
among Caucasians, with an allele frequency typically around 40% in predominantly Caucasian 
populations. Haplotype frequency revealed an incidence of 95% for VKORC1*2 in Chinese 
subjects. This frequency corresponds well with the reported low warfarin dose requirement in 
Chinese and Malay subjects and in Europeans homozygous for VKORC1*2 (Geisen 2005, 
Rieder 2005). This haplotype also exists in African populations, but it is less frequent (Geisen 
2005).  
VKORC1*3 (H7 and H8, haplotype group B (Rieder et al)) is defined by the G9041A 
(3730 G>A, rs7294). G9041 is a SNP in the 3'UTR of VKORC1, and it is associated with a 
higher warfarin dose (D'Andrea 2005, Herman 2006). VKORC1*3 is the most common 
haplotype in the African population, and is also very common among Caucasians (38%) (Geisen 
2005). 
VKORC1*4 (H9, haplotype group B) is defined by the 6009 C>T variant. In the analysis 
of Rieder et al. and Herman et al. VKORC1*4 was associated with a higher dose of warfarin 
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(Rieder 2005, Herman 2006). The occurrence of VKORC1*4 haplotype in Caucasians is about 
20% (Geisen 2005). 
Rieder et al. (2005) identified a low-dose haplotype group (A) and a high-dose haplotype 
group (B). The analogy of haplotypes of VKORC1 gene defined by Rieder and Geisen and the 
classification of haplotypes into haplotype groups are shown in Table 3. 
 
Table 3. Haplotype groups and analogy of haplotypes of VKORC1 gene according to the 
literature 
 
Haplotype 
Geisen et al. Rieder et al. 
Haplotype 
group 
VKORC1*2 H1 and H2 A (low dose) 
VKORC1*3 H7 and H8 
VKORC1*4 H9 
B (high dose) 
 
 
The mean maintenance dose of warfarin differed significantly among the haplotype 
group combinations, at approximately 2.7 mg per day for A/A, 4.9 mg per day for A/B, and 6.2 
mg per day for B/B (p less than 0.001). VKORC1 haplotype groups A and B explained 
approximately 25% of the variance in dose. Asian Americans had a higher proportion of group 
A haplotypes and African Americans a higher proportion of group B haplotypes. In conclusion, 
VKORC1 genotype was found to determine 25-40% of individual coumarin dose requirement 
(Bodin 2005, Schwarz 2006, Cooper 2008). The characterization of both the low-dose and high-
dose defining haplotypes of the VKORC1 gene is clinically helpful, because we can identify 
with a simple test the two critical states of anticoagulated patients: the under- and 
overanticoagulation. 
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1.7.  Human multidrug resistance 1 (MDR1) genetics 
 
P-glycoprotein (P-gp), a large (170 kDa) transmembrane protein, functions as an energy-
dependent drug-transport pump and it is responsible for the multidrug resistance in cancer cells 
(Kimchi-Sarfaty 2007b). P-glycoprotein is essential in building the blood-brain barrier (Schinkel 
1996) and as transporter among other tissues (Fromm 2000), and it is an important prognostic 
factor in several tumor diseases. P-gp plays an important role in the bioavailability of a wide 
variety of drugs, including chemotherapeutic agents, cardiac drugs, antibiotics, steroids, 
immunosuppressants, HIV protease inhibitors and warfarin (Sparreboom 2003, Sakaeda 2002, 
Sakaeda 2005, Cascorbi 2001). Although the phisiological role of P-gp is not fully understood, 
it is conceivable that P-gp may prevent intracellular accumulation of potentially toxic substances 
and metabolites (Schinkel 1996). 
P-gp is the product of the human multidrug resistance 1 (MDR1/ABCB1) gene. MDR1 is 
a typical stress-response gene, and a variety of different drugs potentially interact with MDR1 
transcription, which results in an induction of P-glycoprotein expression (Schinkel 1996). 
MDR1 [MIM 171050] is located on chromosome 7q21.1 and consists of 28 exons (Chen 1990). 
The P-gp has 1280 amino acids, 12 transmembrane domains and two ATP-binding sites (Tang 
2002). MDR1 is constituvely expressed in excretory and barrier tissues, such as the intestines, 
liver, kidney, pancreas, brain, testis, placenta, and so most likely have protective and elimination 
roles (Sakaeda 2005). Whereas MDR1 is highly expressed in cancer cells and plays a key role in 
anticancer and antiviral therapy (Dong 2008). 
Another aspect is important from the viewpoint of human evulutionary genetics. MDR1 
is involved in human resistance to various infections, conferring resistance to bacterial toxins 
and viruses (Schaeffeler 2001). Infections have been the most potent factors of natural selection 
in Homo sapiens populations throughout their history. Hence the genetic variation of MDR1 in 
modern populations is, to a great extent, a product of natural selection (Pel's IaR 2007). 
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MDR1 was among the first transporters extensively screened for genetic polymorphisms. 
Mutational analyses revealed that the MDR1 gene is highly polymorphic, with more than 100 
polymorphic sites with a minor allele frequency greater than 5% (Fromm 2002). Studied 
polymorphisms of the MDR1 gene are summarized in Table 4. 
 
Table 4. Studied polymorphisms of the MDR1 gene 
 
MDR1 
polymorphism rs Protein variant Mutation Location
C1236T 1128503 - synonymous exon 12 
G2677T/A 2032582 Ala893Thr/Ser non-synonymous exon 21 
C3435T 1045642 - synonymous exon 26 
 
Among the MDR1 SNPs many researchers focused on C3435T (rs1045642, Ile1145Ile, 
exon 26) synonymous variant. The C3435T SNP is located in noncoding nonpromoter position 
in the MDR1 gene and hence is unlikely to regulate the expression of MDR1. It is possible that 
this SNP may function in concert with as yet unidentified regions of the MDR1 gene that 
regulate expression. In recent years the relationship between the MDR1 C3435T variant and 
susceptibility to some diseases, such as gastrointestinal tract infections (Schaeffeler 2001), 
Parkinson’s disease (Lee 2004, Drozdzik 2003), nortryptilyne-indused postural hypotension 
(Roberts 2002), renal epithelial tumours (Siegsmund 2002) and childhood acute lymphoblastic 
leukaemia (ALL) (Jamroziak 2004) has been identified. These reports suggested that an 
assessment of C3435T variant could be useful for predicting some P-gp-dependent diseases. 
Individuals, who are homozygous for the 3435T variant, have a significant decrease in 
intestinal P-gp expression, and increased plasma digoxin levels (Hoffmeyer 2000). Further 
studies also shown that 3435C allele is associated with increased and 3435T allele with 
decreased P-gp expression (Siddiqui 2003). Clinical studies have been shown that 3435CC 
genotype is associated with higher probability of complete remission in AML patients (Kim 
2006), with drug-resistant epilepsy (Siddiqui 2003), and predicts longer steroid treatment in 
pediatric heart transplant patients (Zheng 2002). The 3435TT genotype predicted response to 
preoperative chemotherapy for breast cancer (Kafka 2003), and significantly associated with no 
or low level of MDR1 expression in carcinoma cell lines (Sauer 2002). It has been reported, that 
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the distribution of the C3435T polymorphism is significantly influenced by ethnicity (Cascorbi 
2001, Ameyaw 2001, Balram 2003). The frequency of the homozygous CC genotype was 
highest among the African population and lowest in the south-west Asian groups 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1128503) (Kim 2001, Ameyaw 
2001, Schaeffeler 2001). The frequency of 3435C allele is significantly higher in African than 
other ethnic populations. This is consistent with the high incidence of anticancer drug resistance 
and more aggressive tumors in individuals of African origin (Dong 2008).  
 Futher studies revealed that C3435T SNP was closely linked to other common 
polymorphisms, such as C1236T and G2677A/T. The body of work studying the effect of the 
1236 C>T (rs1128503, Gly412Gly, exon 12) synonymous SNP is fairly small, with no 
conclusive findings to date. The 2677G>A/T (rs2032582, Ala893Thr/Ser, exon 21) 
nonsynonymous variant has been well studied. Associations between this SNP and P-gp 
function or expression have not been conclusively determined. Several studies revealed that 
2677A-bearing subjects exhibit higher P-gp activity (Yi 2004). Some positive findings are that 
2677GG is associated with higher probability of complete remission in AML patients (Kim 
2006). The 2677A/T alleles are positive predictors of tacrolimus neurotoxicity in liver transplant 
patients (Yamauchi 2002). The 2677A/T variant also showed variability among different ethnic 
groups. The 2677A allele appeared more common in Japanese and Korean populations (Kim 
2001).  
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Furthermore, haplotype analyses may play an important role in the identification of 
genetic differences between ethnic groups. Using the three common exonic polymorphisms 
enabled us to establish the haplotype profile of the Roma and Hungarian populations by allele 
counting. Haplotype determination of the MDR1 gene is summarized in Table 5. 
 
Table 5. Haplotype determination of MDR1 gene 
 
MDR1 polymorphisms 
C1236T G2677A/T C3435T 
Alleles 
C T G A T C T 
MDR1 
haplotype 
MDR1 
haplotype 
symbol 
1 2 1 2 3 1 2 
CGC 111 1  1   1  
CGT 112 1   1       1 
CAC 121 1     1   1   
CAT 122 1     1     1 
CTC 131 1       1 1   
CTT 132 1       1   1 
TGC 211   1 1     1   
TGT 212   1 1       1 
TAC 221   1   1   1   
TAT 222   1   1     1 
TTC 231   1     1 1   
TTT 232   1     1   1 
 
The functional effects of P-gp activity may also be related to haplotypes in the MDR1 
gene (Kimchi-Sarfaty 2007a). Several clinical studies have shown that the haplotype 1236T-
2677T-3435T is associated with reduced P-gp activity (Wong 2005). 
Some studies revealed that MDR1 haplotypes differed greatly between ethnic groups 
(Kim 2001, Kroetz 2003, Tang 2002, Tang 2004). With respect to global drug development and 
treatment, the distribution of functionally important MDR1 mutations in populations of different 
ethnic origins should be evaluated (Cascorbi 2001). In summary, knowledge of genetic 
variability of ABC transporters between different ethnic groups is relevant pharmacological 
factor that can be used to understand variability in drug response (Balram 2003). 
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1.8. Origin of the Hungarian population: historical perspective 
 
The Hungarians are unique among the other surrounding European populations because 
of the ancestry of the Magyars, the founders of the Hungarian state 1100 years ago (Nadasi 
2007, Semino 2000b). The Hungarian nation traces its history to the early Magyars, who settled 
in the Carpathian Basin at the end of the 9th century after two millennia of migration from 
behind the Urals, via the steppe zone (Serre 2004)(Bálint 1996). This region had been settled for 
thousands of years before the Magyar’s arrival, by Dacians, Romans, Sarmatians, Goths, Huns, 
Avars, Slavs. It is known that at the time of the Hungarian Conquest the majority of the 
indigenous population was Slavic. Estimates of the fraction of the total population of the 
Carpathian-Basin consisting of newly arrived Hungarians ranged from 10 to 50% (Cavalli-
Sforza 1994). 
In order to study the genetic structure in populations living in the Carpatian Basin from 
the time of the Hungarian Conquest, polymorphisms of mitochondrial DNA, Y chromosomal 
binary marker investigations, and also array based SNP studies had been performed. 
The analysis of the maternal lineage shows that the linguistic isolation of Hungarian-
speaking populations in the Carpathian Basin did not lead to significant genetic isolation. 
Mitochondrial DNA sequences of 27 ancient samples (10-11th centuries), 101 contemporary 
Hungarian, and 76 Hungarian-speaking Szekler (isolated minority in Transylvania) samples 
from Transylvania were analyzed (Tomory 2007). The data were compared with sequences of 
7752 individuals representing 57 European and Asian populations, including Finno-Ugric 
populations, and statistical analyses were performed to study their genetic relationships. Only 2 
of 27 ancient Hungarian samples are unambiguously Asian, the rest belong to one of the 
Eurasian haplogroups, but some Asian affinities, and the genetic effect of populations who 
likely mingled with ancient Hungarians during their migrations are seen. Recent Hungarian-
speaking populations possess specifically European mitochondrial haplogroups. The results 
suggest that the ancient population from the 10th-11th centuries was genetically heterogeneous, 
and some Asian genetic influence is seen in the Hungarian conqueror population. In the 
contemporary Hungary, likely there is a dominating effect of populations already living in the 
Carpatian Basin, with influence from the Balkans and West Eurasia, while in the Szeklers the 
genetic effect of Eastern and Southern Europeans is more visible. 
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Paternal lineages, which usually give a higher geographical resolution than maternal, 
have also been studied. Total of 22 biallelic polymorphisms were typed from the non-
recombining region of the human Y chromosome in 100 men from modern Hungary and 97 
Szeklers. The results were compared with data from other European populations studied by 
Semino et al. (Semino 2000a), and the phylogeographic context of the Y chromosome pool of 
the populations has been analysed (Csanyi 2008). One specific Y-chromosomal base 
substitution (Tat, T→C) a relatively recent event (95% confidence interval 3140-6200 years) is 
a valuable marker in Finno-Ugric population studies (Zerjal 1997a). The C allele of the Tat 
polymorphism is widespread in all Uralic-speaking populations, except that it is absent or 
extremely rare among modern Hungarian-speaking populations (Semino 2000a, Zerjal 1997b, 
Lahermo 1999, Semino 2000c, Tambets 2004) (Rootsi 2000, Tambets 2001). Among the 
modern individuals, only one Szekler carries the Tat C allele, whereas out of four skeletal 
remains, from the time of the Hungarian conquest, two possess the allele. The latter finding 
appears to indicate a Siberian lineage of the invading Hungarians, which later has largely 
disappeared. 
In the two recent Hungarian-speaking populations the Y-chromosomal binary markers 
share similar components described for other European populations, except for the presence of 
the haplogroup P*(xM173) in Szekler samples, which may reflect a Central Asian connection, 
and high frequency of haplogroup J in both Szeklers and Hungarians. MDS analysis based on 
haplogroup frequency values, confirms that modern Hungarian and Szekler populations are 
genetically closely related, and similar to populations from Central Europe and the Balkans. 
 Another study analysing a total of 6,501 Y chromosomes of 81 populations, including 
samples collected from 106 random avarage Hungarian males, there was no statistical difference 
in the prevalence of the E-M78 and E-V13 haplogropus between Hungarians and the 
surrounding nations (Cruciani 2007). 
 The lactase non-persistence (hypolactasia) is inherited as an autosomal recessive trait 
(Sahi 1973). The prevalence of adult type lactase non-persistence is 3-70% among Caucasian 
populations in Europe, rare in Northern Europe, but it increases in the south and west. It reaches 
approximately 100% in Asians (Suarez 1997, Gudmand-Hoyer 1996). Recently a T/C SNP 
variant upstream of the LCT gene was proved to be associated with lactase non-persistence, and 
the functional role of C/T-13910 polymorphism in regulation of lactase gene expression was 
characterized (Olds 2003, Troelsen 2003). The prevalence of different C/T-13910 lactase 
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genotypes in recent population of Hungary with random sampling was evaluated. (Nagy 2009) 
Allele frequencies associated with lactase persistence (T-13910) and non-persistence (C-13910) were 
37.8% and 62.2%, respectively. The 62.2% frequency of the lactase persistence in the 
Hungarian population is lower than that in Sweden and Finland (81.5%), higher than in France 
(43.1%) and Northern Italy (35.7%) and similar to Portugal (62%) (Ingram 2009). On the other 
hand the frequency of lactase non-persistence among those recent populations, which lived in 
close vicinity with the Magyars in the Siberian homeland, contrary to the recent Hungarian 
population is similarly high; 71% in Northern Mansi, 78% in Nenets, 50% in Komi-Permiak and 
59% in Udmurtian (Kozlov 1998). 
 More recently, in a study with analysis of more than 270,000 SNPs, genotyped with 
Illumina 318K/370CNV chips, studying 3,112 individuals across 16 European countries, 
including 50 Hungarians, no unique genotype could be revealed in the Hungarian samples, they 
exhibited a high degree of similartity compared with the neighbouring nations (Nelis 2009). 
 
1.9. Roma (Gypsy/Romani) population: origin, Roma in the world and in Hungary 
 
Roma believed to have originated in the northern part of Indian subcontinent. They 
began their migration about 1000 years ago. The reason for their diaspora remains an enigma. 
However, the most probable conclusion is that the Roma were part of the military in Northern 
India. The absence of a written history has meant that the origin and early history of the Romani 
people was long not clear. Roma emigrated from India towards the northwest no earlier than the 
11th century. Contemporary populations sometimes suggested as sharing a close relationship 
with the Roma are the Dom people of Central Asia and the Banjara of India. 
Social sciences, comparative linguistic studies hinted their Asian origin. Genetic 
evidences also suggested the Indian origin of Roma. 47.3% of Romani man carry the Y 
chromosome haplogroup of H-M82 which is rare outside of the Indian subcontinent. 
Mitochondrial haplogroup M most common in Indian subjects and rare outside Southern Asia, 
accounts for nearly 30% of Romani people (Kalaydjieva 2005). A more detailed study of Polish 
Roma shows this to be of the M5 lineage, which is specific to India (Malyarchuk 2006). 
Moreover, a form of the inherited disorder congenital myasthenia is found in Romani subjects. 
This form of the disorder, caused by the 1267delG mutation, is otherwise only known in 
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subjects of Indian ancestry. This is considered to be the best evidence of the Indian ancestry of 
the Romanies (Morar 2004a). 
In conclusion, Gypsies are a conglomerate founder population with Asian roots, 
imbedded into a Caucasian, genetically different population (Kalaydjieva 2005). According to 
the genealogy data Roma could be best described as a mosaic of founder populations, which 
were shaped by their migrations in Europe (Morar 2004b). 
Roma populations live in many countries throughout the world and are well known for 
their preserved traditions. Currently, the total Roma population size is estimated to be about 12 
million in the world, and 8-10 million Gypsies live in Europe today (Morar 2004b, Gresham 
2001a). Hungary is the fourth in Europe considering the estimated size of the Roma population, 
which is about 700.000 people (Gresham 2001a). The Figure 2. shows the distribution of the 
Romani people in Europe. 
 
 
Figure 2. Distribution of the Romani people in Europe (2007 Council of Europe "average 
estimates": 9.8 million) 
* The size of the wheel symbols reflects absolute population size 
* The gradient reflects the percent in the country's population: 0%                              10%. 
(Reference:http://www.coe.int/t/dg3/romatravellers/Documentation/strategies/statistiques_en.as
p#P11_143) 
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The population of Hungary is comprised largely of Hungarians, however, several ethnic 
minorities also reside there, with the Roma forming the largest group (Irwin 2007). The number 
of Roma in Hungary is hard to estimate. According to the census of 2001 the Roma minority has 
about 200.000 members, self identified as Roma. According to the 2008 survey the number of 
Roma is between 600.000 and 800.000 in Hungary (www.ksh.hu). Moreover, the statistical 
survey of sociologists estimates the number of Roma between 600.000 and 1 million in 
Hungary. Figure 3. shows the distribution of Roma in Hungary according to the census in 2001. 
 
 
Figure 3. The distribution of Roma in Hungary (%) according to the census in 2001. 
(Reference: http://en.wikipedia.org/wiki/File:Hungary_roma_2001.PNG) 
 
The Roma in Hungary are composed of three main subpopulations according to their 
history and language: the Romungro, the Olah and the Beas (Crowe 1991). The Romungro 
(Hungarian Roma) is the oldest Roma subpopulation in the Carpathian-Basin. They settled  
around 16th, 17th centuries. They named themselves Hungarian Roma, and they speak Hungarian 
in general. In the past most of them lived in separate, isolated settlements (“colonies”) near the 
villages. The profession of these people is mostly musician, some earned their living with hired 
labour in the agriculture. The most of Roma, about 71%, belong to this group in Hungary. The 
Olah (the Hungarian name of Romanian people) subpopulation got this name because the 
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members of this group came from Romania at the 19th century. The other name of them is 
Wallachian Roma. In the past they were nomads with traditional occupations, connected with 
offering of different kinds of commodities and services. Now Olah Romani people live in all 
regions of Hungary, but mostly in cities. They use the Lovari language and speak Hungarian 
also. Olah people form about 21% of the Romani. The most of Beas (Boyash) Romani people 
live in villages in South-Transdanubian region of Hungary. In this region they form about 30% 
of the whole Romani population. In Baranya and Somogy county the majority of Roma belong 
to the Beas subgroup. Beas speak Hungarian and archaic Roman language, and form only 8% of 
the Romani population (Crowe 1991). 
The greatest number of the Roma was integrated into the Hungarian population, and they 
live together in many settlements of Hungary. The members of the Roma population marry 
traditionally only within their own community. Therefore they preserve a closed genetic system.  
As the Roma and Hungarian have completely other origin, the Roma came from Indian 
subcontinent and Hungarians moved from Asia, they have entirely different genetic structure. 
 Due to the previous international studies, some special hereditary disorders in the rare 
disease categories of the Roma population are already known. Thus, hereditary motor and 
sensory neuropathy, congenital cataracts facial dysmorphysm neuropathy, congenital 
myasthenia syndrome, limb-girdle muscular dystrophy, galactokinase deficiency and polycystic 
kidney disease are known to accumulate in different European Romani populations. The 
accumulation of recessively inherited autosomal multiplex malformation syndromes was 
observed in some Hungarian gypsy colonies. A special form is accepted now as orofaciodigital 
type VI, and as Váradi-Papp syndrome in the McKusick catalogue (OMIM %277170) (Varadi 
1980). High incidence of short rib-polydactyly syndrome type VI was recognized in a 
Hungarian Roma sub-population (Kovacs 2006). A Roma patient with bigenic connexin 
mutations associated with hydrotic ectodermal dysplasia was also observed. The patient 
harbored a novel sporadic mutation (V41L) in GJA1 (Cx43) as well as a heterozygous coding 
variant (R127H) of GJB2 (Cx26) (Kellermayer 2005). Molecular genetic analysis of the 
SLC22A5 gene in two non-consanguineous Hungarian Roma children with carnitine responsive 
cardiomyopathy and in postmortem tissue specimens from sudden infant death cases revealed a 
homozygous deletion of 17081C of the SLC22A5 gene (Melegh 2004). Genomic DNA 
sequencing revealed novel mutation in the signal transducer and activator of transcription 3 gene 
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(STAT3; H332Y) in a Gipsy family (Jiao 2008). Finally, a homozygous K76N mutation was 
also detected in two sisters from a consanguineous Gipsy family (Miltenberger-Miltenyi 2005). 
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2. OBJECTIVES OF THE WORK 
 
Although the polymorphisms of CYP2C9, VKORC1 and MDR1 genes are well 
documented in several populations, there is no report considering the Roma and Hungarian 
populations. In this way the main purposes of the work are: 
 
• To determine the allele frequencies of functionally significant polymorphisms of 
clinically important DME, the CYP2C9, in healthy Hungarian and Roma populations. 
 
• To characterize the allele frequencies of the drug target, VKORC1, in healthy Hungarian 
and Roma population subjects. 
 
• To describe the allele frequencies of most relevant SNP-s of the MDR1 drug transporter 
in healthy Hungarian and Roma population subjects. 
 
• To establish the haplotype profiles of both the VKORC1 and MDR1 genes in healthy 
Hungarian and Roma population samples. 
 
• To compare the allele and haplotype frequencies of CYP2C9, VKORC1 and MDR1 
genes of the Hungarian and Roma populations with results available for other ethnic 
populations in literature, mainly with Caucasian and Indian populations. 
 
• To give useful informations in connection with the origin of the Hungarian and Roma 
populations. 
 
The results would be very useful as serves basis for future drug and disease related studies, 
and could provide information for therapy of many diseases in Hungarian and Roma 
populations.  
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3. MATERIALS AND METHODS 
3.1. Study populations 
 
The study was done using DNA from healthy Roma and healthy Hungarian subjects. The 
Roma and Hungarian Caucasian samples are originated from different regions of Hungary. 
During personal interviews, the Hungarians did not enroll themselves to any minor ethnic 
groups living in Hungary. 
The DNA samples were from the central Biobank of the University of Pecs that is part of 
the National Biobank Network of Hungary (www.biobank.hu). The governance principles and 
maintenance management of the Biobank had been approved by the Hungarian National 
Research Ethics Committee. During the collection and analysis of DNA samples and processing 
of the accompanying clinical and personal data the guidelines and regulations of the Helsinki 
Declaration in 1975 and the currently operative National regulations were followed. 
In CYP2C9 study DNA of total of 535 healthy Hungarian (251 males and 284 females, 
mean age 49±16 years, range: 20-92 years) and 465 healthy Roma samples (300 males and 165 
females, mean age 40±16 years, range: 18-90 years) were used. 
 A total of 510 healthy Hungarian DNA samples (179 males and 331 females, mean age 
41±13 years, range 20-78 years) and 451 samples collected from Roma people (157 males and 
294 females, mean age 42±16 years, range 18-88 years) were used for the VKORC1 study. 
In MDR1 study DNA of total of 503 healthy Hungarian (269 males and 234 females, 
mean age 49±16 years, range: 20-97 years) and 465 healthy Roma samples (167 males and 298 
females, mean age 40±16 years, range: 18-90 years) were used. 
 
3.2. Molecular methods 
 
Genomic DNA was isolated from peripherial leukocytes using routine salting out 
method. In order to genotype the samples we applied PCR/RFLP assays to characterize the 
polymorphisms of studied genes. For primer design the sequences deposited into the GenBank 
were used. PCR amplification was carried out in a final volume of 50 µl containing 200 µM of 
each dNTP, 1 U of Taq polymerase, 5 µl of reaction buffer (10 mM Tris-HCl, pH 9.0, 
containing 500 mM KCl, 14 mM MgCl2), 0.2 mM of each primers and 1 µg DNA extracted on 
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an MJ Research PTC 200 thermal cycler. The amplicons were digested by allele-specific 
restriction endonucleases. In the amplicons there was an obligatory cleavage site to enable us to 
monitor the efficacy of the digestion. The digested PCR products were separated by 
electrophoresis using a 3% agarose gel stained with etidium bromide and were visualized by UV 
illumination. 
 
The CYP2C9*2 (Arg144Cys) mutation was detected using the following forward and 
reverse primers 5’-GGGAGGATGGAAAACAGAGACTT-3’ and  
5’-GGTCAGTGATATGGAGTAG GGTCA-3’, respectively. PCR conditions were as follows: 
predenaturation for 2 min at 95ºC, followed by 40 cycles of denaturation for 30 sec at 95ºC, 
annealing for 30 sec at 55ºC, primer extension for 30 sec at 72ºC, the final extension at 72ºC for 
5 min. 10 µl PCR product was digested by 1U Cfr13I (AsuI) restriction enzyme. In samples with 
CYP2C9*2 CC genotype the Cfr13I cleaves the 309 bp long PCR product into 48 bp, 84 bp and 
177 bp fragments. If the CYP2C9*2 430T allele was present in homozygouse form 48 bp and 
261 bp fragments could be detected (Sipeky 2009b). Genotyping of CYP2C9*3 (Ile359Leu) 
polymorphism was performed as previously described by Sullivan-Klose et al., as this method 
gave highly specific amplification of the CYP2C9 gene confirmed by DNA sequencing 
(Sullivan-Klose 1996, Xie 2002, Yasar 1999). For random control of both the assays we used 
direct sequencing with the same primers utilizing an ABI PRISM 3100 AVANT genetic 
analyser. 
 
Three polymorphisms of the VKORC1 (MIM *608547) gene including c.-1639 G/A 
(3673G/A, M2) in the promoter region, c.492+134 G/A (9041 G/A, M23) in the 3’-UTR region, 
and c.173+525 C/T (6009 C/T, M16) in intron1 were analyzed. 
For determination of the 3673 G/A polymorphism (rs9923231) the following primers 
were used: 5’-ATCCCTCTGGGAAGTCAAGC-3’, and 5’-CACCTTCAACCTCTCCATCC-3’; 
to test the 9041G/A (rs7294) SNP the 5’-TTTAGAGACCCTTCCCAGCA-3’ and 5’-
AGCTCCAGAGAAGGCAACAC -3’ oligonucleotides were used. For the amplification of the 
target sequence of C6009T (rs17708472) the 5’-AGGCGTTAGCATAATGACGG -3’ and 5’-
GGGTGGAACCAGGTTAGGAC-3’ primers were utilized. Annealing temperature for the 3673 
G/A, 9041 G/A and 6009 C/T primers were 60°C, 59°C and 65°C, respectively. The 636 bp 
amplicon of VKORC1 3673 G/A SNP was digested with BcnI endonuclease. In the samples 
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with GG genotype the digestion resulted in 50, 114 and 472 bp fragments; in AA homozygotes 
114 and 522 bp fragments were produced. The SsiI was used to cleave the 674 bp PCR product 
of VKORC1 G9041A variant. For GG homozygotes 117, 216 and 341 bp products, while in AA 
homozygotes 117 and 557 bp restriction fragments could be detected. For the C6009T 
polymorphism the FspBI enzyme was used and the following fragments of the 725 bp amplicon 
could be detected: 109 and 616 bp sequences for the major allele (C), 109, 133 and 483 bp for 
the minor allele (T) (Sipeky 2009a). Approximately 10% of the total PCR products were 
selected randomly for direct sequencing to confirm the results obtained by PCR-PFLP procedure 
by an ABI PRISM 3100 AVANT Genetic Analyser. 
 
Three polymorphisms of the MDR1 (MIM*171050) gene including C1236T (exon 12), 
G2677T/A (exon 21), and C3435T (exon 26) were analyzed. 
For detection of the C1236T (rs1128503) polymorphism the following primers were 
used: 5’-AGCTATTCGAAGAGTGGGCA-3’, and 5’-GTCTAGCTCGCATGGGTCAT-3’. The 
G2677T/A (Ala893Thr/Ser) (rs2032582) SNP was detected using two set of primers: 5'-
GGTTCCAGGCTTGCTGT AAT-3’ (1) forward, 5’- TTTAGTTTGACTCACCTTCCCTG-3’ 
(1) reverse, and 5’-CAGCATTCTGAAGTCATGGAA-3’ (2) forward, 5’-
GTCCAAGAACTGGCTTT GCT-3’ (2) reverse. For the amplification of the target sequence of 
C3435T (rs1045642) the 5’-GATGTCTTGTGGGAGAGGGA-3’ and 5’-
GCATGTATGTTGGCCTCCTT-3’ primers were utilized. PCR conditions were as follows: 
predenaturation for 2 min at 96ºC, followed by 35 cycles of denaturation for 30 sec at 95ºC, 
annealing for 30 sec by primer specific temperature, primer extension for 30 sec at 72ºC, the 
final extension at 72ºC for 5 min. Annealing temperature for the C1236T, G2677T/A (1), 
G2677T/A (2) and C3435T primers were 57°C, 57°C, 55°C and 56°C, respectively. 10 µl PCR 
product of the C1236T, G2677T/A (1), G2677T/A (2) and C3435T primers was digested by 
BsuRI, HpyCH4V, RsaI and MboI restriction enzymes, respectively. In the samples with 1236 
CC genotype the BsuRI cleaves the 418 bp long PCR product in 35 bp, 105 bp and 278 bp 
fragments. If the 1236 T allele was present in homozygouse form the 105 bp and 313 bp 
fragments could be detected. For GG homozygotes the 213 bp PCR product (first set of primers) 
of G2677T/A variant was digested into 23, 72, and 118 bp fragments. By the presence of G and 
A/T basis (A group) the digestion resulted in 23, 72, 95, 118 bp fragments; and if the A/T basis 
(B group) were presented 95 and 118 bp amplicons could be detected. All the samples analysed 
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with the first set of primers were amplified by the help of second set of primers except the 
samples with GG genotype. If the digestion of the 577 bp PCR amplicon of the second set of 
G2677T/A primers resulted in 277 and 300 bp fragments: GT (A group) and TT (B group) 
genotypes could be detected; by the presence of 82, 195, 277 and 300 bp fragments the GA (A 
group) and TA (B group) genotypes could be detected. In the samples with AA homozygous 
genotype the digestion resulted in 82, 195 and 300 bp fragments. The 451 bp amplicon of the 
C3435T SNP in the samples with CC genotype was digested into 34, 172 and 245 bp long 
fragments; in TT homozygotes the digestion resulted in 206 and 245 bp fragments (Sipeky 
2010). For random control of the assays we used direct sequencing with the same primers 
utilizing an ABI PRISM 3100 AVANT genetic analyser. 
 
3.3. Statistical analyses of data 
 
We used the Chi-square test (nonparametric test for discrete variables) to compare the 
differences between the two groups studied. The value of p<0.05 was considered as statistically 
significant. Statistical analyses were performed applying Excel for Windows and SPSS 11.5 
package for Windows (SPSS Inc., Chicago, IL). 
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4. RESULTS 
4.1. CYP2C9 gene 
 
The distribution of CYP2C9*1, *2, *3 alleles as well the *1/*1, *1/*2, *1/*3, *2/*2, 
*2/*3, *3/*3 genotypes in Hungarian and Roma populations are presented in Table 6. 
 
Table 6. Allele and genotype frequencies and the predicted phenotype of CYP2C9 in the healthy 
Hungarian and Roma population samples; data are compared with those reported for Indian and 
Caucasian populations. 
Current study Reported data 
CYP2C9 Hungarian  
n=535 
Roma      
n=465 
Indian 
(Adithan 
2003)      
n=135 
Italian 
Caucasian 
(Scordo 
2004) 
n=360 
Allele frequency         
*1 0.787 0.727a,b 0.907 0.778 
*2 0.125 0.118b 0.026 0.125 
*3 0.088 0.155a,b,c 0.067 0.097 
Genotype frequency         
*1/*1 0.620 0.533a,b,c 0.823 0.619 
*1/*2 0.195 0.168b 0.044 0.172 
*1/*3 0.139 0.219a,b,c 0.127 0.145 
*2/*2 0.021 0.011 ND 0.028 
*2/*3 0.015 0.047a,b 0.007 0.022 
*3/*3 0.011 0.022 ND 0.014 
Phenotype frequency         
wt/wt (EM) 0.620 0.533a,b,c 0.823 0.619 
wt/mut (IM) 0.334 0.387b,c 0.171 0.317 
mut/mut (PM) 0.047 0.080a,b 0.007 0.064 
ap<0.03, when Roma are compared with Hungarian population 
bp<0.04, when Roma are compared with Indian population 
cp<0.04, when Roma are compared with Caucasian population 
No significant difference was observed between Hungarian and Caucasian population considering the CYP2C9 gene. 
n, number of subjects 
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All CYP2C9 allele and genotype frequencies were in Hardy-Weinberg equilibrium both 
in Roma and in Hungarian subjects. Beside the wild-type allele, the CYP2C9*2 was the most 
common allele identified in Hungarians, while in the Roma population the CYP2C9*3 was the 
most frequent. In addition, we found a significant (1.8-fold) increase in CYP2C9*3 prevalence 
in Roma population compared to Hungarian samples, which has therapeutic consequences 
(p<0.001). Furthermore, the frequency of *1/*3 genotype observed here was considerably 
higher in the Roma group than in Hungarians (0.219 vs. 0.139, p<0.001). Interestingly, the 
*1/*1 genotype in the Hungarian population was more common than in Roma subjects 
(p<0.005). Based on the distribution of CYP2C9 gene variants, the proportion of subjects 
homozygous for the wild-type allele (genotypically identified as extensive metabolizer, EM) 
was higher in Hungarians (p<0.005), while subjects carrying two detrimental alleles (with 
impaired enzyme activity, poor metabolizer, PM) are more frequent in Roma population 
(p<0.03). 
Many studies have shown interethnic differences in the frequencies of CYP2C9 alleles. The 
results of this study were also compared with compiled data reported for other populations, with 
special regard to the Caucasian population and the Indians (Table 6. and Table 7.) (Adithan 
2003, Scordo 2004).  
 Table 7. Comparison of allele and genotype frequencies of CYP2C9 reported from different ethnic populations 
CYP2C9 alleles CYP2C9 genotypes Populations 
 n *1 *2 *3 *1/*1 *1/*2 *1/*3 *2/*2 *2/*3 *3/*3 
Ref. 
Hungarian (patient) 421 0.814 0.110 0.076 0.656 0.185 0.131 0.007 0.021 ND (Mark 2006) 
Croatian 200 0.740 0.165 0.095 0.740 0.225 0.035 (Bozina 2003) 
Italian (healthy) 360 0.778 0.125 0.097 0.619 0.172 0.145 0.028 0.022 0.014 (Scordo 2004) 
Italian (healthy) 157 0.796 0.112 0.092 0.650 0.153 0.140 0.025 0.019 0.013 (Scordo 2001) 
Caucasian 325 0.784 0.124 0.092 0.606 0.203 0.157 0.012 0.016 ND (Gaedigk 2001) 
Swedish (healthy) 430 0.819 0.107 0.074 0.667 0.186 0.116 0.005 0.019 0.007 (Yasar 1999) 
Spanish (healthy) 102 0.745 0.156 0.098 0.578 0.196 0.137 0.039 0.039 0.01 (Dorado 2003) 
Spanish (healthy) 157 0.694 0.143 0.162 0.497 0.159 0.235 0.019 0.089 ND (Garcia-Martin 2001) 
*Belgian 121 0.822 0.100 0.074 0.670 0.182 0.116 ND 0.016 0.008 (Allabi 2003) 
British 561 0.841 0.110 0.053 0.699 0.191 0.095 0.005 0.011 ND (Taube 2000) 
British 100 0.790 0.125 0.085 0.620 0.190 0.150 0.030 ND 0.010 (Stubbins 1996) 
White-American 140 0.825 0.132 0.043 0.671 0.221 0.086 0.021 ND ND (Dickmann 2001) 
White-American 100 0.860 0.080 0.060 0.720 0.160 0.120 ND ND ND (Sullivan-Klose 1996) 
Afro-American 100 0.985 0.010 0.005 0.970 0.020 0.010 ND ND ND (Sullivan-Klose 1996) 
Afro-American 120 0.946 0.025 0.013 0.892 0.050 0.025 ND ND ND (Dickmann 2001) 
Mexican-American 98 0.86 0.08 0.06 0.74 0.15 0.1 ND 0.01 ND (LLerena 2004) 
Canadian Indian 114 0.910 0.030 0.060 0.825 0.061 0.114 ND ND ND (Gaedigk 2001) 
Inuit 151 0.100 ND ND 0.100 ND ND ND ND ND (Gaedigk 2001) 
Ethiopian 150 0.933 0.043 0.023 0.867 0.087 0.046 ND ND ND (Scordo 2001) 
*Beninese 111 0.955 ND ND 0.910 ND ND ND ND ND (Allabi 2003) 
Egyptians 247 0.820 0.120 0.060 0.664 0.190 0.117 0.024 ND 0.004 (Hamdy 2002) 
Chinese 115 0.983 ND 0.017 0.965 ND 0.035 ND ND ND (Wang 1995) 
Chinese 102 0.951 ND 0.049 0.892 ND 0.108 ND ND ND (Gaedigk 2001) 
Japanese 140 0.982 ND 0.018 0.964 ND 0.036 ND ND ND (Kimura 1998) 
Japanese 218 0.979 ND 0.021 0.959 ND 0.041 ND ND ND (Nasu 1997) 
Korean 574 0.989 ND 0.011 0.977 ND 0.023 ND ND ND (Yoon 2001) 
Taiwanese 98 0.974 ND 0.026 0.918 ND 0.082 ND ND ND (Sullivan-Klose 1996) 
Turkish 499 0.794 0.106 0.100 0.617 0.180 0.172 0.010 0.011 0.008 (Aynacioglu 1999) 
Iranian 160 0.793 0.110 0.097 0.644 0.175 0.137 0.025 ND 0.019 (Peyvandi 2002) 
Indian (healthy) 135 0.907 0.026 0.067 0.823 0.044 0.127 ND 0.007 ND (Adithan 2003) 
Faroese (Denmark) 311 0.867 0.088 0.053 0.733 0.177 0.106 ND 0.016 ND (Halling 2005) 
Bolivian 778 0.992 0.048 0.03 0.847 0.093 0.057 ND 0.004 ND (Bravo-Villalta 2005) 
n, number of subjects; ND, not detectable; *There were other alleles and genotypes also detected 
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 4.2. VKORC1 gene 
 
All VKORC1 allele frequencies were in Hardy-Weinberg equilibrium both in Hungarian, 
and in Roma subjects. The frequency of allelic variants and genotypes of VKORC1 tagging 
polymorphisms in the Roma group and Hungarians are summarized in Table 8. 
 
Table 8. VKORC1 haplotype tagging SNPs in Roma and Hungarian populations; data are also 
compared with data reported from India, or deposited into database for Caucasians. 
 
Current study Data from other studies 
VKORC1 
polymorphism Genotype 
Roma       
n=451       
(%) 
Hungarian   
n=510       
(%) 
Indian (Lee 
2006)   n=43  
(%) 
Caucasian 
(NCBI) 
n=22/n=23/ 
n=21 (%) 
GG 214 (47.5) 180 (35.3)a 36 (83.8)b 7 (31.8) 
GA 206 (45.7) 262 (51.4) 4 (9.50)b 11 (50.0) 
AA 31 (6.87) 68 (13.3)a 3 (6.80) 4 (18.2)c 
GA+AA 237 (52.6) 330 (64.7)a 7 (16.3)b 15 (68.2) 
G-1639A 
A allele 
frequency 0.297 (29.7) 0.390 (39.0)
a 0.116 (11.6)b 0.432 (43.2) 
GG 132 (29.3) 206 (40.4)a 4 (8.10)b 10 (43.5) 
GA 220 (48.8) 233 (45.7) 8 (18.9)b 11 (47.8) 
AA 99 (22.0) 71 (13.9)a 31 (73.0)b 2 (8.7) 
GA+AA 319 (70.8) 304 (59.6)a 39 (91.9)b 13 (56.5) 
G9041A 
A allele 
frequency 0.463 (46.3) 0.368 (36.8)
a 0.814 (81.4)b 0.326 (32.6) 
CC 293 (65.0) 319 (62.5) 38 (87.8)b 13 (61.9) 
CT 144 (31.9) 170 (33.3) 5 (12.2)b 7 (33.3) 
TT 14 (3.10) 21 (4.12) 0 (0.00) 1 (4.80) 
CT+TT 158 (35.0) 191 (37.4) 5 (12.2)b 8 (38.1) 
C6009T 
T allele 
frequency 0.191 (19.1) 0.208 (20.8) 0.058 (5.8)
b 0.214 (21.4) 
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www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9923231;www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?r
s=7294;www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17708472 
aHungarian population is compared with Roma; p<0.001 
bIndian population is compared with Roma; p<0.01 
cCaucasian population is comapred with Roma; p<0.05 
 
For the G-1639A polymorphism significant differences were observed in the prevalence 
of homozygous GG and AA genotypes, GA+AA carriers, and in minor allele frequency between 
the Roma and Hungarian samples (p<0.001); for the G9041A SNP exactly the same distribution 
patterns could be detected. By contrast, the genotype and allele distributions for the C6009T 
SNP did not differ between Roma and Hungarians (Table 8.). 
In the Hungarian population sample (Table 9.) the haplotypes in decreasing order of their 
frequencies were the *2 (39%), *3 (37%), *4 (21%) and *1 (3%), while in the Roma population 
samples *3 (46%), *2 (30%), *4 (19%), and *1 (5%). The statistical analysis revealed 
significant difference in the prevalence rate of VKORC1*2 and VKORC1*3 haplotypes 
between the Roma and average Hungarian population (p<0.005). 
 Table 9. Ethnic distribution of VKORC1 haplotype frequencies.  
 
Americans with origin of (Rieder 2005) Haplotype 
identification 
code 
Hungarian  
(n=510) 
Roma     
(n=451) 
European 
(Geisen 
2005) GER   
(n=200) 
Italian 
(Spreafico 
2008) 
(n=220) 
Israeli 
(Loebstein 
2007) 
(n=99)† 
Chinese 
(Perlegen)   
CHN  
(n=24) 
African 
(Perlegen) 
AFR     
(n=23) 
European 
(n=186)†
European 
(n=119)† 
Asian 
(n=120)†
African 
(n=96)† 
VKORC1*1 0.03 (35) 0.05 (44) <0.001 0.03 (15) 0.01 <0.001 0.31 (14) <0.001 <0.001 <0.001 <0.001 
VKORC1*2 0.39 (400)a 0.30 (269) 0.42 (168) 0.43 (189) 0.41 0.95 (46) 0.14 (6) 0.36 (131) 0.38 (89) 0.89 (213) 0.13 (26) 
VKORC1*3 0.37 (373)a 0.46 (417) 0.38 (152) 0.36 (158) 0.37 0.04 (2) 0.43 (20) 0.43 (160) 0.35 (83) 0.10 (25) 0.43 (82) 
VKORC1*4 0.21 (212) 0.19 (172) 0.20 (80) 0.18 (78) 0.18 <0.01 0.12 (6) 0.21 (77) 0.24 (56) <0.01 (2) 0.06 (11) 
 
Chinese (www.perlegen.com) 
African (www.perlegen.com) 
aHungarian population is compared with Roma; p<0.005 
†Other haplotypes were also identified in low percentile rates. 
Haplotype <0.001 means that this haplotype was not found, but its existence cannot be excluded (definition is from Geisen 2005) 
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By using the above VKORC1 haplotypes we could determine the VKORC1 genotypes of 
each subject in the studied populations (Table 10.). 
 
Table 10. VKORC1 genotype distribution in Roma, Hungarian and Italian Caucasian 
population, and the predicted warfarin dose. 
 
Genotype frequency (%) 
VKORC1 
genotypes Predicted dose 
Roma        
n=451 (%) 
(healthy) 
Hungarian 
n=510 (%) 
(healthy) 
Italian 
(Spreafico 
2008)        
n=220 (%) 
(anticoagulated) 
*1/*1 Ancestral† 1 (0.22) 1 (0.20) 0 (0.00) 
*1/*2 Ancestral/Low† 14 (3.10) 18 (3.53) 3 (1.4) 
*1/*3 Ancestral/High† 18 (3.99) 15 (2.94) 8 (3.6) 
*1/*4 Ancestral/High† 10 (2.22) 0 (0.00)a 4 (1.8)c 
*2/*2 Low 31 (6.87) 69 (13.6)a 48 (21.8)b,c 
*2/*3 Intermediate 130 (28.8) 146 (28.6) 60 (27.3) 
*2/*4 Intermediate 63 (14.0) 98 (19.2)a 30 (13.6) 
*3/*3 High 99 (22.0) 70 (13.8)a 29 (13.2)b 
*3/*4 High 71 (15.7) 72 (14.1) 32 (14.5) 
*4/*4 High 14 (3.10) 21 (4.12) 6 (2.7) 
†Functional significance of these genotypes is still not clear. 
aHungarian population is compared with Roma; p<0.04 
bItalian population is compared with Roma; p<0.01 
cItalian population is compared with Hungarian; p<0.01 
 
The ancestral VKORC1 *1/*1 genotype could be found both in Roma and in 
Hungarians. This ancestral genotype was also detected in combination with other genotypes 
(*1/*2, *1/*3, *1/*4), but the *1/*4 was not detectable in Hungarian population. Comparing the 
Roma with the Hungarians significant difference was observed in prevalence of *1/*4, 
*2/*2,*2/*4 and *3/*3 genotypes (p<0.04). 
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4.3. MDR1 gene 
 
The allele and genotype frequencies of studied MDR1 polymorphisms in the Hungarian 
group and Roma are shown in Table 11. 
 
Table 11. Allele and genotype frequencies of MDR1 in the healthy Hungarian and Roma 
population samples; data are compared with those reported for Indian and Caucasian 
populations. 
Current study Reported data 
MDR1   
SNP 
Genotype 
and allele 
Roma       
n=465       
(%) 
Hungarian  
n=503      
(%) 
Indian 
(Lakhan 
2009) 
n=96, 
n=101,    
n=97      
(%) 
German 
Caucasian 
(Cascorbi 
2001) 
n=461      
(%) 
CC 96 (20.7)a,c 167 (33.2) 15 (15.6) 158 (34.4) 
CT 226 (48.6) 226 (44.9) 45 (46.9) 227 (49.2) 
TT 143 (30.8)a,c 110 (21.9)d 36 (37.5) 76 (16.4) 
Carrier 369 (79.4)a,c 336 (66.8) 81 (84.4) 303 (65.6) 
C1236T 
T allele 
frequency 0.551
a,c 0.443 0.609 0.410 
GG 125 (26.9)b 154 (30.6) 14 (13.9) 143 (30.9) 
GT 228 (49.0) 235 (46.7) 48 (47.5) 227 (49.2) 
TT 94 (20.2) 103 (20.5) 26 (25.7) 74 (16.1) 
GA 11 (2.37) 8 (1.59) 4 (4.00) 9 (2.00) 
TA 6 (1.30)b 3 (0.60) 9 (8.90) 8 (1.80) 
AA 1 (0.22) 0 (0.00) 0 (0.00) 0 (0.00) 
Carrier 340 (73.1)b 349 (69.4) 87 (86.1) 318 (69.1) 
T allele 
frequency 0.454
b 0.441 0.540 0.416 
G2677T/A 
A allele 
frequency 0.020
b 0.011 0.064 0.019 
CC 124 (26.7)c 112 (22.3) 24 (24.7) 96 (20.8) 
CT 234 (50.3) 252 (50.1) 40 (41.2) 233 (50.5) 
TT 107 (23.0)b 139 (27.6) 33 (34.0) 132 (28.6) 
Carrier 341 (73.3)c 391 (77.7) 73 (75.2) 365 (79.1) 
C3435T 
T allele 
frequency 0.482
a,c 0.527 0.546 0.539 
ap<0.04, when Roma are compared with Hungarian population 
bp<0.02, when Roma are compared with Indian population 
cp<0.03, when Roma are compared with Caucasian population 
dp<0.03, when Hungarians are compared with Caucasian population 
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The allele and genotype frequencies of studied MDR1 SNPs did not show a significant 
deviation from Hardy-Weinberg equilibrium neither in Roma nor in Hungarian subjects. 
Considering the MDR1 C1236T polymorphism, a significant difference was observed in 
the presence of CC (20.7 vs. 33.2%) and TT (30.8 vs. 21.9%) genotypes, the CT+TT (79.4 vs. 
66.8%) carriers and the T allele frequency in Roma compared to Hungarians (p<0.002), 
respectively. The 1236C (0.557) was the most common allele identified in Hungarians, while in 
Roma population the 1236T (0.551) allele was most frequent. By contrast, no significant 
difference was observed between Roma and Hungarian populations considering the G2677T/A 
polymorphism. However, subjects carrying two of mutated alleles (TA) are two-times more 
common in Roma population than in Hungarians (1.3 vs. 0.6%). The frequency of the 2677A 
allele was almost two-fold higher in Roma than in Hungarian group, however the difference did 
not reach the statistical significance level (0.020 vs. 0.011, p=0.078). In MDR1 exon 26 
(C3435T), higher frequency of the T allele was observed in Hungarians compared with Roma 
(0.527 vs. 0.482, p<0.05). 
The genetic variability of the major MDR1 polymorphisms vary among several ethnic 
groups and are summarized in Table 12. 
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Table 12. (A) Comparison of allele and genotype frequencies of MDR1 C1236T  
(exon 12) polymorphism reported from different ethnic populations (ND, not detected 
NA, not analized) 
 
Genotype frequency Allele frequency Population n 
CC CT TT T 
References 
Caucasians             
Czech 189 0.317 0.471 0.212 0.447 (Pechandova 2006) 
Polish 96 0.291 0.563 0.146 0.427 (Jamroziak 2009) 
Polish 139 0.353 0.468 0.180 0.414 (Tan 2004) 
Polish 135 0.304 0.496 0.200 0.448 (Wasilewska 2007) 
German 188 0.380 0.490 0.130 0.380 (Hoffmeyer 2000) 
Russian 59 0.240 0.560 0.200 0.483 (Goreva 2004) 
French 223 0.330 0.490 0.180 0.424 (Jeannesson 2007) 
Portuguese 100 0.270 0.550 0.180 0.455 (Jeannesson 2007) 
Slovenian 355 0.164 0.447 0.389 0.390 (Potocnik 2008) 
Caucasian 97 0.299 0.485 0.216 0.459 (Komoto 2006) 
European Caucasian 60 0.350 0.517 0.133 0.392 [100] 
Asians             
Japanese 154 0.110 0.468 0.422 0.656 (Komoto 2006) 
Japanese 45 0.178 0.489 0.333 0.578 [100] 
Chinese Han 165 0.115 0.497 0.388 0.636 (Li 2007) 
Chinese Uygur 161 0.161 0.491 0.348 0.407 (Li 2007) 
Chinese Kazakh 108 0.139 0.380 0.481 0.329 (Li 2007) 
Chinese Han 200 0.105 0.475 0.420 0.657 (Zhang 2008) 
Chinese 206 0.155 0.413 0.432 0.638 (Tan 2005) 
Chinese 96 0.083 0.396 0.521 0.718 (Chowbay 2003) 
Malay 92 0.120 0.446 0.435 0.658 (Chowbay 2003) 
Indian 87 0.138 0.379 0.483 0.672 (Chowbay 2003) 
Chinese 45 0.111 0.400 0.489 0.689 [100] 
Others             
Brazilians (White) 106 0.400 0.390 0.210 0.410 (Estrela 2008) 
Brazilians (Intermediate) 114 0.470 0.380 0.160 0.340 (Estrela 2008) 
Brazilians (Black) 100 0.460 0.410 0.130 0.330 (Estrela 2008) 
Ashkenazi Jewish 101 0.400 0.370 0.240 0.420 (Kimchi-Sarfaty 2007a) 
Turkish 100 0.200 0.510 0.290 0.545 (Gumus-Akay 2008)
Sub-Saharan African 57 0.772 0.211 0.018 0.123 [100] 
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(B) Comparison of allele and genotype frequencies of MDR1 G2677T/A (exon 21) polymorphism reported from different ethnic 
populations 
Genotype frequency Allele frequency 
Population n 
GG GT TT TA GA AA T  A 
References 
Caucasians   
Czech 189 0.296 0.471 0.222 ND 0.050 ND 0.458 0.003 (Pechandova 2006)
Polish 96 0.333 0.532 0.135 ND ND ND 0.401 ND (Jamroziak 2009)
Polish 139 0.339 0.468 0.173 0.014 0.007 ND 0.414 0.576 (Tan 2004)
Polish 204 0.387 0.397 0.176 0.020 0.020 ND 0.385 0.020 (Kurzawski 2006)
British 285 0.329 0.474 0.147 0.025 0.025 ND 0.396 0.025 (Onnie 2006)
Scottish 370 0.276 0.470 0.254 NA NA NA 0.498 NA (Ho 2005)
Italian 450 0.280 0.524 0.153 0.016 0.027 ND 0.423 0.021 (Palmieri 2005)
Russian 290 0.303 0.449 0.183 0.024 0.041 0.000 0.419 0.033 (Gaikovitch 2003)
Slovenian 355 0.375 0.445 0.180 NA NA NA 0.400 NA (Potocnik 2008)
Caucasian 98 0.276 0.418 0.245 0.020 0.031 0.010 0.464 0.036 (Komoto 2006)
European Caucasian 59 0.322 0.559 0.119 ND ND ND 0.398 ND [101]
Asians   
Japanese 154 0.195 0.318 0.182 0.130 0.149 0.026 0.406 0.166 (Komoto 2006)
Japanese 117 0.128 0.385 0.094 0.137 0.239 0.017 0.355 0.205 (Horinouchi 2002)
Chinese 206 0.277 0.388 0.131 0.078 0.102 0.024 0.364 0.114 (Tan 2005)
Chinese Han 200 0.175 0.375 0.210 0.105 0.110 0.025 0.450 0.133 (Zhang 2008)
Chinese Han 165 0.200 0.382 0.164 0.133 0.109 0.012 0.421 0.133 (Li 2007)
Chinese Uygur 161 0.217 0.429 0.267 0.050 0.037 0.000 0.506 0.043 (Li 2007)
Chinese Kazakh 108 0.269 0.343 0.185 0.065 0.139 0.000 0.389 0.102 (Li 2007)
Indian 87 0.138 0.310 0.414 0.058 0.081 ND 0.598 0.069 (Chowbay 2003)
Korean 632 0.191 0.339 0.163 0.117 0.155 0.035 0.391 0.171 (Lee 2005)
Vietnamese 142 0.393 0.303 0.176 0.030 0.098 ND 0.356 0.063 (Lee 2005)
Asian 23 0.130 0.261 0.304 0.174 0.130 ND 0.522 0.152 [101]
Others   
Bulgarian 160 0.344 0.431 0.225 NA NA NA 0.441 NA (Petrova 2008)
Brazilians (White) 106 0.400 0.400 0.180 ND 0.020 ND 0.380 0.010 (Estrela 2008)
Brazilians (Intermediate) 114 0.500 0.380 0.080 0.020 0.020 ND 0.280 0.020 (Estrela 2008)
Brazilians (Black) 100 0.650 0.330 0.010 0.010 ND ND 0.180 0.010 (Estrela 2008)
Ashkenazi Jewish 101 0.360 0.480 0.170 NA NA NA 0.410 NA (Kimchi-Sarfaty 2007a)
Turkish 70 0.300 0.443 0.257 ND ND ND 0.470 ND (Sapmaz 2008)
Sub-Saharan African 60 1.000 ND ND ND ND ND ND ND [101]
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(C) Comparison of allele and genotype frequencies of MDR1 C3435T (exon 26) 
polymorphism reported from different ethnic populations 
Genotype frequency Allele frequency Population n 
CC CT TT T 
References 
Caucasians             
Czech 189 0.212 0.449 0.339 0.564 (Pechandova 2006) 
Polish 96 0.281 0.500 0.219 0.469 (Jamroziak 2009) 
Polish 139 0.216 0.525 0.259 0.522 (Tan 2004) 
Polish 122 0.420 0.410 0.170 0.380 (Jamroziak 2002) 
Polish (West) 204 0.220 0.510 0.270 0.520 (Kurzawski 2006) 
German 188 0.278 0.483 0.239 0.481 (Hoffmeyer 2000) 
British 190 0.240 0.480 0.280 0.420 (Ameyaw 2001) 
British 280 0.218 0.486 0.296 0.539 (Onnie 2006) 
Russian 290 0.214 0.486 0.300 0.543 (Gaikovitch 2003) 
Italian 450 0.256 0.533 0.211 0.478 (Palmieri 2005) 
Spanish 408 0.260 0.520 0.220 0.480 (Bernal 2003) 
Spanish (North) 204 0.270 0.510 0.220 0.480 (Vicente 2008) 
French 81 0.360 0.420 0.220 0.430 (Anglicheau 2003) 
Portuguese 100 0.220 0.420 0.360 0.570 (Ameyaw 2001) 
Slovenian 355 0.227 0.487 0.286 0.530 (Potocnik 2008) 
Caucasian 99 0.212 0.444 0.343 0.566 (Komoto 2006) 
European Caucasian 58 0.155 0.603 0.241 0.543 [102] 
Asians             
Japanese 154 0.357 0.474 0.169 0.406 (Komoto 2006) 
Japanese 114 0.351 0.526 0.123 0.386 (Sakaeda 2001) 
Japanese 168 0.292 0.571 0.137 0.423 (Sugimoto 2008) 
Japanese 48 0.290 0.440 0.270 0.490 (Tanabe 2001) 
Japanese 50 0.340 0.460 0.200 0.430 (Schaeffeler 2001) 
Japanese 117 0.350 0.530 0.120 0.385 (Horinouchi 2002) 
Japanese 44 0.250 0.545 0.205 0.477 [102] 
Chinese 206 0.422 0.461 0.117 0.347 (Tan 2005) 
Chinese 45 0.400 0.400 0.200 0.400 [102] 
Chinese Han 200 0.300 0.535 0.165 0.433 (Zhang 2008) 
Chinese Han 179 0.380 0.514 0.106 0.363 (Kwan 2007) 
Chinese Han 265 0.320 0.480 0.200 0.440 (Li 2006) 
Chinese Han 165 0.382 0.479 0.139 0.379 (Li 2007) 
Chinese Uygur 161 0.248 0.447 0.304 0.528 (Li 2007) 
Chinese Kazakh 108 0.380 0.444 0.176 0.398 (Li 2007) 
Lahu (Southern China) 104 0.163 0.587 0.250 0.543 (Dong 2008) 
Wa (Southern China) 101 0.297 0.495 0.208 0.455 (Dong 2008) 
Bulang (Southern China) 100 0.360 0.500 0.140 0.390 (Dong 2008) 
Han Chinese (Hong Kong) 199 0.447 0.442 0.111 0.332 (Dong 2008) 
Chinese (Malaysia) 288 0.372 0.489 0.139 0.384 (Teh 2007) 
Chinese (Singapore) 98 0.245 0.439 0.316 0.541 (Balram 2003) 
Chinese (Southwest) 132 0.318 0.424 0.258 0.470 (Ameyaw 2001) 
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Chinese (Singapore) 224 0.280 0.500 0.220 0.410 (Lee 2004) 
Indian 87 0.184 0.368 0.448 0.632 (Chowbay 2003) 
Tamilians (South India) 185 0.180 0.560 0.260 0.540 (Ramasamy 2006) 
Indian (Malaysia) 171 0.170 0.438 0.392 0.611 (Teh 2007) 
Indian (Singapore) 93 0.180 0.390 0.430 0.620 (Balram 2003) 
Malay (Malaysia) 304 0.362 0.487 0.151 0.395 (Teh 2007) 
Malay (Singapore) 99 0.253 0.465 0.283 0.520 (Balram 2003) 
Vietnamese 142 0.451 0.366 0.183 0.366 (Lee 2005) 
Vietnamese (Kinh) 72 0.319 0.556 0.125 0.403 (Veiga 2009) 
Korean 632 0.384 0.445 0.171 0.393 (Lee 2005) 
Iranian 300 0.440 0.450 0.110 0.201 (Farnood 2007) 
Filipino 60 0.380 0.420 0.200 0.410 (Ameyaw 2001) 
Saudi 96 0.370 0.380 0.260 0.450 (Ameyaw 2001) 
Southwest Asians 89 0.150 0.380 0.47 0.663 (Ameyaw 2001) 
Africans             
Egyptian 50 0.240 0.480 0.280 0.520 (Ebid 2007) 
Egyptian 200 0.340 0.515 0.145 0.403 (Hamdy 2003) 
Ghanaian 206 0.670 0.340 0.000 0.170 (Ameyaw 2001) 
Kenyan 80 0.700 0.260 0.040 0.170 (Ameyaw 2001) 
Sudanese 51 0.520 0.430 0.060 0.270 (Ameyaw 2001) 
African-American 88 0.680 0.310 0.010 0.165 (Ameyaw 2001) 
Sub-Saharan African 59 0.797 0.186 0.017 0.110 [102] 
South-Americans             
Brazilians (White) 106 0.320 0.450 0.230 0.450 (Estrela 2008) 
Brazilians (Intermediate) 114 0.400 0.520 0.080 0.340 (Estrela 2008) 
Brazilians (Black) 100 0.500 0.410 0.090 0.310 (Estrela 2008) 
Chilean (Pascuense) 52 0.560 0.380 0.060 0.250 (Wielandt 2004) 
Chilean (Mestizo) 104 0.460 0.430 0.120 0.330 (Wielandt 2004) 
Chilean (Mapuche) 96 0.490 0.310 0.200 0.350 (Wielandt 2004) 
Others             
Central American 229 0.290 0.470 0.240 0.470 (Vicente 2008) 
Bulgarian  160 0.269 0.444 0.287 0.509 (Petrova 2008) 
Ashkenazi Jewish 101 0.310 0.390 0.310 0.500 (Kimchi-Sarfaty 2007a) 
Turkish                    
(Aegean-Denizli Province) 150 0.200 0.530 0.270 0.530 (Turgut 2006) 
Turkish (Southeast) 96 0.290 0.470 0.240 0.474 (Kerb 2001) 
Ashkenazi Jewish 100 0.420 0.460 0.120 0.350 (Ostrovsky 2004) 
New Zealander 160 0.210 0.520 0.270 0.530 (Roberts 2002) 
 
Reference internet sites: 
[100] http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1128503 
[101] http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2032582 
[102] http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1045642 
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Subsequent analyses of the MDR1 haplotype frequencies, estimated from the genotype 
data, were compared between the two studied groups (Table 13.). 
 
Table 13. Haplotype frequencies derived from C1236T, G2677T/A and C3435T 
polymorphisms of MDR1 gene in healthy Roma and Hungarian populations 
 
Haplotype frequency n (%) 
Number 
of 
haplotypes 
Haplotype Roma 
n=465 
Hungarian 
n=503 
Czech 
(Bandur 
2008) 
n=533 
Caucasian 
(Kroetz 
2003) 
n=247 
Indian 
(South) 
(epilepsy) 
(Vahab 
2009) 
n=129 
1 TTT 335 (36.0)b,c,d 377 (37.5)f 419 (39.3) 101 (41.0) 33 (25.2)
2 CGC 328 (35.3)a,c,d 416 (41.4)e,f 398 (37.3) 91 (37.0) 18 (13.6)
3 TGC 68 (7.31)a,b,c 17 (1.68) 30 (2.80) 3 (1.00) 14 (11.0)
4 TTC 62 (6.67)a,b,c,d 21 (2.08) 13 (1.20) 6 (2.50) 8 (6.20) 
5 CGT 56 (6.02)a,b 91 (9.04)f 103 (9.70) 29 (12.0) 13 (9.90)
6 TGT 37 (3.98)b,c 27 (2.68)f 22 (2.10) 1 (0.50) 9 (7.10) 
7 CTC 15 (1.61) 17 (1.68) 27 (2.50) 4 (1.50) 5 (4.20) 
8 CTT 10 (1.08)a,b,d 29 (2.88)f 32 (3.00) 3 (1.00) 29 (22.8)
9 TAT 7 (0.75)b,c 4 (0.39)e ND ND ND 
10 CAC 6 (0.65)b 4 (0.39)e 17 (1.60) 6 (2.50) ND 
11 CAT 3 (0.32) 3 (0.29) 5 (0.50) 3 (1.00) ND 
12 TAC 3 (0.32) ND ND ND ND 
ND, not detected 
ap<0.009, when Roma are compared with Hungarian population 
bp<0.04, when Roma are compared with Czech population 
cp<0.05, when Roma are compared with Caucasian population 
dp<0.02, when Roma are compared with Indian population 
ep<0.03, when Hungarians are compared with Czech population 
fp<0.02, when Hungarians are compared with Caucasian population  
 
There were 12 possible MDR1 haplotypes and the frequencies of these were 
statistically different between the Roma and Hungarian populations. All 12 possible 
haplotypes were observed in Roma, compared with 11 haplotypes in Hungarians. The 
1236T/2677A/3435C haplotype was not detectable in Hungarian population. The two most 
frequent MDR1 haplotypes both in Roma and Hungarian populations were TTT (36.0 vs. 
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37.5%) and CGC (35.3 vs. 41.4%). The haplotypes TTT, CGC, TGC, TTC, CGT occured at 
high frequencies in Roma population (6.02-36.0%), whereas in Hungarians TTT, CGC and 
CGT were the most common identified haplotypes. The statistical analysis revealed 
significant difference in the prevalence rate of CGC, TGC, TTC, CGT and CTT haplotypes 
between the healthy Roma and Hungarian populations (p<0.009). The occurrence of 
1236T/2677G/3435C haplotype was four-fold higher in Roma than in Hungarians. In 
addition, the presence of 1236T/2677T/3435C haplotype was three-fold higher in Roma than 
in Hungarians. Whereas the frequency of 1236C/2677T/3435T haplotype was two-fold higher 
in Hungarian than in Roma group. 
Comparison of haplotype profile of both studied groups and other populations is also 
provided in Table 13. and Table 14. For the Caucasians two sets of data are listed, as there 
were considerable differences between the two groups found in the literature. The Roma 
population showed significant differences in TTT, CGC, TGC, TTC, CGT, TGT, CTT, TAT, 
CAC haplotypes when compared to Caucasians and to the Czech population (p<0.05) (Table 
13.) (Kroetz 2003, Bandur 2008). However, Roma were more similar to the Indian population 
and difference could be observed only in TTT, CGC, TTC and CTT haplotypes (p<0.02) 
(Vahab 2009). The haplotype structure of Hungarian population differed also from the 
Caucasian and Czech populations. Significant difference was found in TTT, CGC, CGT, 
TGT, CTT, TAT and CAC haplotypes (p<0.03) (Kroetz 2003, Bandur 2008). In a previous 
study of Hungarian acute lymphoblastic leukaemia patients the dominating haplotypes were 
TTT and CGC, in accordance with our results (Erdelyi 2006). 
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Table 14. Comparison of haplotype frequencies of MDR1 gene reported from different ethnic populations 
 
Haplotype frequency (%) 
Number 
of 
haplotypes 
Haplotype 
Chinese 
Han (Li 
2007) 
n=165 
Chinese 
Uygur 
(Li 
2007) 
n=161 
Chinese 
Kazakh 
(Li 
2007) 
n=108 
Korean 
(epilepsy) 
(Kim 
2006) 
n=99 
Ashkenazi 
Jewish 
(Kimchi-
Sarfaty 
2007a) 
n=101 
Tuvinians 
(Pel's IaR 
2007) 
n=142 
Kyrgyz 
(South) 
(Pel's 
IaR 
2007) 
n=44 
Kyrgyz 
(North) 
(Pel's 
IaR 
2007) 
n=41 
Japanese 
(Komoto 
2006) 
n=154 
1 TTT 33.3 45.3 34.5 15.7 23.6 31.67 25.25 33.1 36.4 
2 CGC 20.1 30.1 21.9 17.2 31.7 23.48 24.76 18.7 16.2 
3 TGC 22.2 8.60 24.8 19.4 6.90 5.43 14.4 6.07 22.7 
4 TTC 5.60 2.20 4.40 9.13 5.20 7.66 5.40 2.72 3.90 
5 CGT 1.20 3.10 1.50 ND 14.4 12.46 8.94 10.86 1.30 
6 TGT 1.00 3.30 2.70 4.68 6.40 7.58 11.08 16.86 2.60 
7 CTC 1.70 2.00 ND 16.1 6.20 0.42 4.05 ND ND 
8 CTT 1.60 1.10 ND 1.44 5.60 2.14 ND 2.93 0.30 
9 TAT 0.40 ND ND 8.95 NA 0.89 ND ND ND 
10 CAC 11.3 4.30 8.40 6.62 NA 6.39 3.43 8.75 16.6 
11 CAT 0.40 ND 1.10 ND NA 1.24 2.69 ND ND 
12 TAC 1.20 ND 0.70 0.59 NA 0.64 ND ND ND 
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5. DISCUSSION 
5.1. CYP2C9 gene 
 
Much of the interindividual and interethnic differences in effects of drugs are 
attributed nowadays in part to genetic differences in their metabolism and utilization (Sadee 
2005). A number of drugs are metabolized by the human cytochrome P450 system (Xie 
2001). The CYP2C9 is the most abundant of the CYP2C enzymes (Lapple 2003). It is 
involved in the metabolism of more than 100 drugs (Kirchheiner 2005, Miners 1998). It is 
well known that the metabolism of S-enantiomers of coumarins, warfarin, acenocoumarol and 
phenprocoumon, was significantly decreased by the presence of both the CYP2C9*2 and 
CYP2C9*3 alleles (Scordo 2002, Kirchheiner 2005, Kamali 2004, Lindh 2008, Becquemont 
2008). Administration of genotype-adjusted dosage of drugs having narrow therapeutic range 
may result in faster anticoagulation and reduced toxicity (Takahashi 2003, Higashi 2002). 
The prevalence of CYP2C9*2 and *3 alleles observed in our study of healthy Hungarian 
subjects were very close to that found in Hungarian patients (Mark 2006) and other Caucasian 
populations (Scordo 2004, Xie 2002, Yasar 1999, Bozina 2003, Scordo 2001, Gaedigk 2001, 
Dorado 2003, Allabi 2003, Taube 2000, Stubbins 1996), but proved to be higher than in 
Orientals (Sullivan-Klose 1996, Gaedigk 2001, Wang 1995, Kimura 1998, Nasu 1997, Yoon 
2001) (Table 7.). Interestingly, CYP2C9*2 and *3 variants appear to be more prevalent in 
Europeans and white Americans (8-16% and 4-9%, respectively) (Sullivan-Klose 1996, 
Scordo 2004, Yasar 1999, Mark 2006, Bozina 2003, Scordo 2001, Gaedigk 2001, Dorado 
2003, Allabi 2003, Taube 2000, Dickmann 2001) than in Asians (0% and 1-5%, respectively) 
or African-Americans (1-2% and 0.5-1%, respectively) (Sullivan-Klose 1996, Gaedigk 2001, 
Dickmann 2001, Wang 1995, Kimura 1998, Yoon 2001). Moreover, the allele frequencies of 
CYP2C9*2 and CYP2C9*3 tend to decrease from West to East (Table 7.). 
Although the *3/*3 genotype frequency in numerous studies was very low or not 
detectable, in Hungarians it seems to be in a higher range among Caucasians (Garcia-Martin 
2006, Scordo 2004, Yasar 1999, Mark 2006, Bozina 2003, Scordo 2001, Gaedigk 2001, 
Dorado 2003, Allabi 2003, Taube 2000, Stubbins 1996). Similarly, we found the homozygous 
mutants for the *3 polymorphism in Roma population samples at the highest frequency level 
(0.022) considering the published literature (Table 7.). It has been shown that *3/*3 genotype 
is associated with clinically significant alterations in the pharmacokinetics of CYP2C9 
substrates, therefore our finding in healthy Hungarian and especially in Roma population is of 
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special clinical importance (Scordo 2002, Kirchheiner 2007, Lee 2002). We found significant 
differences in the genotype and allele frequencies of CYP2C9*2 and *3 variants in Roma 
group versus the Indian population (p<0.04) published in the literature, except the *2/*2 and 
*3/*3 genotypes, which were not detected in Indians (Adithan 2003). In addition, significant 
differences were found in *3 allele frequency and the *1/*1, *1/*3 genotype prevalence 
between the Roma group and other Caucasian population (p<0.04) (Scordo 2004). It has been 
suggested that the CYP2C9*3 allele is responsible for the largest reduction in metabolic 
activity in vitro, as compared to *1 (Lee 2002), thus the higher proportion of *3 allele (0.155) 
in Roma population compared to other ethnic groups is of special importance (Sullivan-Klose 
1996, Scordo 2004, Yasar 1999, Mark 2006, Bozina 2003, Scordo 2001, Gaedigk 2001, 
Dorado 2003, Allabi 2003, Taube 2000, Dickmann 2001, Wang 1995, Kimura 1998, Nasu 
1997, Yoon 2001, Adithan 2003, Stubbins 1996, Lee 2002, Hamdy 2002, LLerena 2004, 
Aynacioglu 1999, Peyvandi 2002, Halling 2005, Bravo-Villalta 2005). 
Taken these findings together, this is the first study to document the allele and genotype 
frequencies of two major variants of CYP2C9 gene in healthy Roma and Hungarian 
population samples. The distribution of CYP2C9 alleles in Roma population showed variation 
when compared with Hungarians, Indians and Caucasians. The analyses of allele and 
genotype frequencies both in Hungarian and Roma populations and their comparison with 
data obtained in other ethnic groups provide genetic evidence of the origin of different 
populations. 
 
5.2. VKORC1 gene 
 
Oral anticoagulant dose requirements vary across ethnic groups, by and large the 
Chinese and Japanese people require lower, while African-Americans need higher doses than 
the Caucasians (Dang 2005, Gan 2003). Polymorphisms in CYP2C9 and VKORC1 account 
for 5–22% and 6–37% of the inter-individual variability of warfarin response, respectively; 
thus, VKORC1 has high impact on the ethnic differences of warfarin sensitivity (El Rouby 
2004, Rieder 2005, Geisen 2005, Yuan 2005, Scott 2008, Osman 2006, Oner 2008, Lee 
2006). The current knowledge about the genetic background determining the anticoagulant 
therapy derives from studies carried out mainly in populations of American, Western 
European or Asian origin; this is the first study about the allele, haplotype, and genotype 
frequencies of VKORC1 gene in Hungarian and Roma population samples. 
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The clinical significance of the VKORC1 comes from the genetic variations in the 
warfarin-treated individuals. In the literature the most extensively studied level is the 
haplotype-tagging SNP and the haplotype analysis. Besides to comparing them to each other, 
we compared our results of VKORC1 tagging SNP-s with data reported for people from India 
(Lee 2006) because of the postulated origin of the Roma tribes, and also with European 
Caucasian(www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9923231,www.ncbi.nlm.nih.gov/SNP/
snp_ref.cgi?rs=7294,www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17708472) populations 
(Table 8.). While difference was seen for G-1639A and G9041A variants between the 
Hungarians and Roma, no considerable difference was observed between Hungarian and 
Caucasian population for these and also for C6009T haplotype-tagging SNPs 
(www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9923231,www.ncbi.nlm.nih.gov/SNP/snp_ref.cg
i?rs=7294, www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17708472). The latter observation is 
consistent with the growing body of observations suggesting, that despite of the origin of the 
ancient tribes, the majority of the modern Hungarians do not differ from the European 
Caucasian lineages (Nadasi 2007). The Roma population was compared to data from India 
(Lee 2006), and with the exception of the -1639AA variant, significant differences were 
observed for all SNPs. The difference in VKORC1 haplotype tagging SNPs between the 
Roma studied by us and the Indian population reported can be attributable to the fact that in 
the subcontinent of India ethnogeographycally distinct subpopulations can be found. Thus, 
available data we cited could cover only a part of heterogeneity of such populations. 
However, in the literature no other data are available for VKORC1 tagging SNPs for people 
of India so far. 
Special interest is devoted to the -1639G/A polymorphism, which occures at the 
second nucleotide of an E-box (CANNTG) in the 5’-untranslated region of the gene (Yuan 
2005). This polymorphism has an important role on VKORC1 gene promoter activity, being 
associated with variable mRNA levels. Actually the G allele shows a 44% increase of the 
gene transcription activity when compared with the A allele, since the A allele disrupts the 
binding of a transcription factor in VKORC1 promoter region, therefore fewer functional 
copies of the mature VKORC1 protein are synthesized, associating thereby ultimately with 
low-warfarin-dose phenotype (Yuan 2005). In Japanese (Obayashi 2006, Kimura 2007) and 
Chinese (Yuan 2005, Wang 2008) subjects the frequency of the VKORC1 -1639AA genotype 
is significantly higher than in Caucasians  (Bodin 2005). Homozygous carriers of -1639A 
allele, which occurres in humans only in the *2/*2 genotype (see below), require the lowest 
dose of coumarin and require therefore special care to prevent the serious bleeding 
  50
complications. In Hungarians we found this genotype essentially in the same range as in 
Caucasians reported by others (Geisen 2005, Sconce 2005), while the Roma findings of ours 
more resembled to that reported previously by others for population samples from India 
(Table 8). This can fit to the data about origin of the Gypsies, however, differences in other 
SNPs do not support this assumption. 
In the VKORC1 population genetic studies the haplotype profile is the second most 
frequently studied in the literature. Besides our findings, in Table 9. we also summarized 
some relevant population-specific data reported by others. While significant difference was 
found in VKORC1*1 and VKORC1*2 haplotype frequencies between Roma and European 
population reported (Geisen 2005), however, comparing the Hungarian and European 
population difference could be observed only in the frequency of VKORC1*1 haplotype, 
while the distribution of VKORC1*2, *3, *4 haplotypes in average Hungarian samples were 
consistent with the profiles characteristic for European Caucasians (Geisen 2005), and the 
Hungarian profile was similar also to the European American sample representatives (Rieder 
2005). 
For the daily clinical patient care the whole VKORC1 genetic status characterizing the 
patient’s warfarin need is required; this is possible with simultaneous characterization of both 
alleles (i.e. both haplotypes) of the patients. The patients can be conventionally stratified into 
low-, intermediate- and the high-warfarin-dose requiring genotypes 
(www.warfarindosing.org/Source/Home.aspx). Despite of this clinical significance, the 
research papers reporting the genotypes in different population studies are rarer. Moreover, 
another type of clinical classification is also available (Rieder 2005). Comparing the 
genotypes of Roma and Hungarian populations using a widespread and simple method, 
difference was found in the *2/*2, *2/*4, and 3*3 natural VKORC1 genomic haplotype 
combinations, individually each representing the low-, intermediate- and the high-warfarin-
dose requiring genotypes, respectively. The *2/*2 genotype frequency was approximately half 
in Roma population compared with the Hungarian samples, but in Italian Caucasians 
(Spreafico 2008) it was almost twice as common as in Hungarians (Table 10.). The *3/*3 
genotype, requiring the highest dose, was more frequent in Roma than in Italian Caucasians 
(Spreafico 2008). 
The results of our study show, that albeit the VKORC1 genetic profile of a mixed 
average Hungarian population exhibited some differences when compared with surrounding 
European Caucasians or Americans of European origin, the data suggest relatively high 
degree of similarity. By contrast, the VKORC1 profiles of Roma people show an isolated 
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genetic structure from the surrounding populations, the data available from India are also not 
consistent with our results found in the Roma population samples. 
5.3. MDR1 gene 
 
Interethnic differences in response to drugs have been related to genotypic variants of 
key enzymes and proteins that affect the safety and efficacy of a drug in the individual patient 
(Evans 1999b). MDR1 polymorphisms alter P-gp conformation and inhibit its function by 
changing the substrate specificity, which results in decreased activity of P-gp (Hoffmeyer 
2000, Kimchi-Sarfaty 2007a). 
The results of this study were compared with compiled data of MDR1 gene 
polymorphisms reported for other populations (Table 11.). The frequency of 1236T allele 
vary between 0.123 in Sub-Saharan African population 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1128503) and 0.718 in Chinese 
(Chowbay 2003); with Asians in higher range (0.656-0.718) (Komoto 2006, Li 2007, Zhang 
2008, Tan 2005, Chowbay 2003) and Caucasians in lower range (0.380-0.483) (Pechandova 
2006, Jamroziak 2009, Tan 2004, Wasilewska 2007, Hoffmeyer 2000, Goreva 2004, 
Jeannesson 2007, Potocnik 2008, Komoto 2006). The 1236T allele frequency in Hungarians 
(0.443) was similar to most other Caucasians. Interestingly, the 1236T allele frequency in the 
Roma population differs significantly from the Caucasians (0.551 vs. 0.410, p<0.001) 
(Cascorbi 2001) and was very similar to that found in Indian populations (0.609, 0.672) 
(Lakhan 2009, Chowbay 2003).  
The frequency of the T allele in exon 21 (G2677A/T) shows also variations when 
compared between ethnic groups. The lowest frequency was observed in Brazilians (0.180) 
(Estrela 2008) and the highest in Indians (0.598) (Chowbay 2003) . The frequency of 2677A 
allele vary between 0.003 in Checz population (Pechandova 2006) and 0.576 in Polish (Tan 
2004), and could not be detected in a number of populations. Interestingly, we did not find 
any difference in G2677A/T genotype and allele distribution between both of our studied 
groups and the Caucasian population (Cascorbi 2001). However, the Roma population differs 
from the Indians in 2677T and 2677A allele frequencies both (p<0.004) (Lakhan 2009). 
However, the 3435T allele ranged from 0.110 in Sub-Saharan African 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1045642) to 0.663 in Southwest 
Asian population (Ameyaw 2001). Studies in African populations reported far less frequent 
presence of the 3435T allele: Ghanaian and Kenyan 0.170 both, Sudanese 0.270, African-
American 0.165 (Ameyaw 2001), except the Egyiptians (0.403, 0.520) (Ebid 2007, Hamdy 
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2003). The dominance of the C allele may be a consequence of natural selection representing 
an advantage against gastrointestinal tract infections (Schaeffeler 2001). The Hungarians were 
very similar to the Caucasians in 3435T allele frequency. Considering the 3435T allele 
frequency in the Roma population we can conclude that the Roma population differs 
significantly from the Caucasians (p<0.01) (Cascorbi 2001), but the frequency found in Roma 
was also much lower than in Indians (Lakhan 2009, Chowbay 2003, Ramasamy 2006, Teh 
2007, Balram 2003). 
The majority of studies have focused on C3435T SNP alone, instead of accounting for 
all the polymorphisms potentially linked in each subject (Woodahl 2004). To explain the 
association between the MDR1 genotype and clinical outcome in different ethnic groups 
haplotype considerations are needed. From the findings in the literature it is clear that the 
establishment of detailed ABCB1 gene haplotype profiles specific for each ethnic group is 
important (Sai 2006). Few of the MDR1 haplotypes have shown association to phenotypes 
with over-expression of the protein (Hoffmeyer 2000). Bandur et al. reported that the CGT 
haplotype increased the risk of acute rejection 1.4 times in renal transplant patients (Bandur 
2008). The CGC, TGC and TTT haplotypes were previously associated with drug resistant 
epilepsy (Vahab 2009). Futhermore, in the study of Panczyk et al. the TTT haplotype was 
associated with colorectal cancer (Panczyk 2009). A detailed description of haplotype profile 
of other populations is also provided in Table 14. Interestingly, in Chinese and Japanese 
populations dominates three haplotypes, the TTT, CGC and the TGC too (Table 14.) (Li 
2007, Komoto 2006). In the Korean people the MDR1 haplotypes split more evenly, with 
TGC, CGC, CTC and TTT the largest proportion (Kim 2006). In Asian groups there are also 
some haplotypes that could not be detected (Kim 2006, Li 2007, Pel's IaR 2007, Komoto 
2006). The distribution of MDR1 haplotypes in Hungarian population is very similar to the 
Ashkenazi Jewish group (Kimchi-Sarfaty 2007a). 
In conclusion, this is the first major study reporting the MDR1 polymorphisms and 
haplotypes in Hungarian and Roma populations too. The Roma population differed 
significantly from the Hungarians and Caucasians in most of MDR1 variants studied, and also 
from the Indians. Our findings revealed that Roma people are at increased risk of drug-
induced side effects and resistance development to a number of drugs due to diminished drug 
elimination, compared to the Hungarian population. In addition, we can conclude that 
Hungarians did not differ significantly from the Caucasians in major MDR1 variants, but 
some difference was observed in MDR1 haplotype structure of the individual persons. Results 
considering the distribution of MDR1 polymorphisms and haplotypes in populations of 
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different origin may contribute to explaining interindividual and interethnic differences in 
drug response and side-effects.
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6. SUMMARY OF NEW OBSERVATIONS 
 
1. According to our results there is a significant increase in CYP2C9*3 prevalence in 
Roma population compared to Hungarian samples. We found homozygous mutants for the *3 
polymorphism in Hungarians and in Roma in a higher range considering the published 
literature. The proportion of extensive metabolizers is higher in Hungarians, while poor 
metabolizers are more frequent in Roma. 
2. We showed significant difference of VKORC1 G-1639A polymorphism and 
VKORC1*2 and VKORC1*3 haplotypes between the Roma and Hungarian samples. No 
considerable difference was observed between Hungarian and Caucasian population for the 
VKORC1 SNPs and distribution of VKORC1*2, *3, *4 haplotypes. Except of the -1639AA 
variant significant difference was observed for all VKORC1 SNPs between the Roma and 
Indian populations, and for VKORC1*1 and VKORC1*2 haplotype frequencies between 
Roma and European population. 
3. We presented a significant difference in the MDR1 C1236T polymorphism, while no 
difference was observed in the G2677T/A SNP between the Roma and Hungarians, and 
higher frequency of the 3435T allele was observed in Hungarians. We found difference in the 
prevalence rate of CGC, TGC, TTC, CGT and CTT haplotypes between the healthy Roma 
and Hungarian populations, and of CGC, TGC, TTC, CGT, TGT, CTT, TAT, CAC 
haplotypes between the Roma and Caucasians. Difference could be observed only in TTT, 
CGC, TTC and CTT haplotypes when comparing Roma to Indians. The haplotype structure of 
Hungarian population differed in TTT, CGC, CGT, TGT, CTT, TAT and CAC haplotypes 
from Caucasians. 
4. We demonstrated that the CYP2C9, VKORC1 and MDR1 genetic profile of average 
Hungarian population is relatively similar to that observed in Caucasian populations. 
Contrarily, the Roma population differs from Hungarians, from most of other Caucasians and 
from Indians in the incidence of selected pharmacogenetically relevant genes. 
5. Evaluation of genetic profile of CYP2C9, VKORC1 and MDR1 genes in two biggest 
populations in Hungary help to characterize their pharmacogenetic profile, to reach the goal 
of personalized medicine and to estimate the global genetic diversity. 
6. Through this study several new pharmacogenetic diagnostic methods are available in 
routine for Hungarian patients, and serve as basis for genotype-assessed dosing regimen and 
lowering the risk of therapeutic failure. 
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